{"parentUuid":null,"isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":"Tu révises (V2) l'article \"PP405\" du blog Dr Emrah Cinik. Tom veut en faire un ARTICLE PHARE, plus fort que la concurrence. C'est le sujet pharma n°1 en volume FR.\n\nFICHIER : /opt/automator/cinik-writer-transtor/files/articles/pp405.md (Read en entier d'abord)\nLis aussi : /opt/automator/cinik-writer-transtor/files/_CONSIGNE_REVISION.md et /opt/automator/cinik-writer-transtor/files/_TON_CINIK.md\n\n## Commentaire de Tom (PRIORITAIRE) :\n\"Trouve un titre légèrement plus clickable, sans être putaclick. Plus de gras et VACHEMENT plus complet, il faut vraiment être fort sur cet article. Les concurrents font mieux : Serkan Aygin fait un article en 3 parties (https://www.drserkanaygin.com/blog/pp405-hair-stem-cell-science-part-1/).\"\n\nDonc :\n1. **Analyse la concurrence** : WebFetch sur https://www.drserkanaygin.com/blog/pp405-hair-stem-cell-science-part-1/ (et les parties 2 et 3 si tu trouves les URLs, essaie part-2 / part-3). Repère les angles qu'ils couvrent, pour faire AUSSI BIEN ou mieux. Ne copie pas, inspire-toi de la profondeur.\n2. **Recherche complémentaire** : WebSearch + WebFetch sur PP405 / Pelage Pharmaceuticals / mécanisme MPC lactate / essais cliniques / calendrier phase 3 / comparaison avec minoxidil et finastéride / autres pistes régénératives concurrentes (verteporfine, exosomes, clonage capillaire). Récupère des données VÉRIFIÉES et récentes. NE JAMAIS inventer de chiffre ni de source.\n3. **Article VACHEMENT plus complet** : vise 2200-2800 mots. Ajoute des sections : contexte (pourquoi c'est une révolution potentielle), mécanisme détaillé et vulgarisé, ce que disent précisément les essais (phase 1, 2a, 2b, calendrier phase 3), PP405 vs traitements actuels (tableau comparatif markdown bienvenu), PP405 vs autres innovations, qui pourra en bénéficier / qui non, FAQ éventuelle, et la transition honnête vers ce que le Dr Cinik propose AUJOURD'HUI (greffe + médecine régénérative) en attendant.\n4. **Titre plus accrocheur** (pas putaclick) : reformule H1 + Title SEO. Garde le mot-clé \"PP405\" en tête du Title.\n5. **Beaucoup de gras** sur chiffres et idées fortes + listes à puces là où c'est utile.\n\n## Règles (voir consigne) :\n- ZÉRO em/en dash. Bloc SEO en tête (Slug, Title ≤60c \" | Dr Cinik\", Meta ≤155c).\n- AUCUNE citation \"(Auteur, année)\" dans le corps : fonds en prose. Garde une section \"Références scientifiques\" APA en bas, ENRICHIE des nouvelles sources que tu trouves (avec URLs réelles vérifiées).\n- **PAS de tableau \"Liens internes recommandés\"** en fin. Garde/ajoute les liens internes DANS le corps (markdown, URLs emrahcinik.com du fichier d'origine + nouveaux pertinents).\n- Titres sans majuscule à chaque mot, nombres sans séparateur, jamais de prix.\n\nÉcris dans le MÊME fichier avec Write. Ordre : bloc SEO, ---, # H1, article, Références (pas de tableau de liens).\nRéponse courte : nouveau H1, Title (+nb car), Meta (+nb car), nb mots, nb sources APA, ce que tu as repris/amélioré vs Serkan Aygin, confirmations (zéro citation corps / pas de tableau liens / zéro dash)."},"uuid":"b54a39e6-5120-4d0b-9b88-94239e274a7c","timestamp":"2026-06-01T09:32:53.108Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"b54a39e6-5120-4d0b-9b88-94239e274a7c","isSidechain":true,"agentId":"aed12d95d36273e8c","attachment":{"type":"deferred_tools_delta","addedNames":["CronCreate","CronDelete","CronList","EnterWorktree","ExitWorktree","ListMcpResourcesTool","Monitor","NotebookEdit","PushNotification","ReadMcpResourceTool","RemoteTrigger","TaskCreate","TaskGet","TaskList","TaskStop","TaskUpdate","WebFetch","WebSearch","mcp__EstimanouContent__add_article_block","mcp__EstimanouContent__add_block","mcp__EstimanouContent__create_article","mcp__EstimanouContent__create_page","mcp__EstimanouContent__delete_article","mcp__EstimanouContent__delete_article_block","mcp__EstimanouContent__delete_block","mcp__EstimanouContent__get_article","mcp__EstimanouContent__get_city_page","mcp__EstimanouContent__get_page","mcp__EstimanouContent__list_articles","mcp__EstimanouContent__list_available_blocks","mcp__EstimanouContent__list_city_pages","mcp__EstimanouContent__list_pages","mcp__EstimanouContent__list_site_urls","mcp__EstimanouContent__reorder_article_blocks","mcp__EstimanouContent__reorder_blocks","mcp__EstimanouContent__replace_article_content","mcp__EstimanouContent__replace_city_seo_content","mcp__EstimanouContent__replace_page_layout","mcp__EstimanouContent__search_internal_links","mcp__EstimanouContent__update_article","mcp__EstimanouContent__update_article_block","mcp__EstimanouContent__update_block","mcp__EstimanouContent__update_city_page_content","mcp__claude_ai_Ahref__batch-analysis","mcp__claude_ai_Ahref__brand-radar-ai-responses","mcp__claude_ai_Ahref__brand-radar-ai-responses-entities","mcp__claude_ai_Ahref__brand-radar-cited-domains","mcp__claude_ai_Ahref__brand-radar-cited-domains-entities","mcp__claude_ai_Ahref__brand-radar-cited-pages","mcp__claude_ai_Ahref__brand-radar-cited-pages-entities","mcp__claude_ai_Ahref__brand-radar-impressions-history","mcp__claude_ai_Ahref__brand-radar-impressions-history-entities","mcp__claude_ai_Ahref__brand-radar-impressions-overview","mcp__claude_ai_Ahref__brand-radar-impressions-overview-entities","mcp__claude_ai_Ahref__brand-radar-mentions-history","mcp__claude_ai_Ahref__brand-radar-mentions-history-entities","mcp__claude_ai_Ahref__brand-radar-mentions-overview","mcp__claude_ai_Ahref__brand-radar-mentions-overview-entities","mcp__claude_ai_Ahref__brand-radar-sov-history","mcp__claude_ai_Ahref__brand-radar-sov-history-entities","mcp__claude_ai_Ahref__brand-radar-sov-overview","mcp__claude_ai_Ahref__brand-radar-sov-overview-entities","mcp__claude_ai_Ahref__doc","mcp__claude_ai_Ahref__gsc-anonymous-queries","mcp__claude_ai_Ahref__gsc-ctr-by-position","mcp__claude_ai_Ahref__gsc-keyword-history","mcp__claude_ai_Ahref__gsc-keywords","mcp__claude_ai_Ahref__gsc-metrics-by-country","mcp__claude_ai_Ahref__gsc-page-history","mcp__claude_ai_Ahref__gsc-pages","mcp__claude_ai_Ahref__gsc-pages-history","mcp__claude_ai_Ahref__gsc-performance-by-device","mcp__claude_ai_Ahref__gsc-performance-by-position","mcp__claude_ai_Ahref__gsc-performance-history","mcp__claude_ai_Ahref__gsc-positions-history","mcp__claude_ai_Ahref__keywords-explorer-matching-terms","mcp__claude_ai_Ahref__keywords-explorer-overview","mcp__claude_ai_Ahref__keywords-explorer-related-terms","mcp__claude_ai_Ahref__keywords-explorer-search-suggestions","mcp__claude_ai_Ahref__keywords-explorer-volume-by-country","mcp__claude_ai_Ahref__keywords-explorer-volume-history","mcp__claude_ai_Ahref__management-brand-radar-prompts","mcp__claude_ai_Ahref__management-brand-radar-reports","mcp__claude_ai_Ahref__management-keyword-list-keywords","mcp__claude_ai_Ahref__management-locations","mcp__claude_ai_Ahref__management-project-competitors","mcp__claude_ai_Ahref__management-project-keywords","mcp__claude_ai_Ahref__management-projects","mcp__claude_ai_Ahref__public-crawler-ip-ranges","mcp__claude_ai_Ahref__public-crawler-ips","mcp__claude_ai_Ahref__rank-tracker-competitors-domains","mcp__claude_ai_Ahref__rank-tracker-competitors-overview","mcp__claude_ai_Ahref__rank-tracker-competitors-pages","mcp__claude_ai_Ahref__rank-tracker-competitors-stats","mcp__claude_ai_Ahref__rank-tracker-overview","mcp__claude_ai_Ahref__rank-tracker-serp-overview","mcp__claude_ai_Ahref__render-data-table","mcp__claude_ai_Ahref__render-scorecard","mcp__claude_ai_Ahref__render-time-series-chart","mcp__claude_ai_Ahref__serp-overview","mcp__claude_ai_Ahref__site-audit-issues","mcp__claude_ai_Ahref__site-audit-page-content","mcp__claude_ai_Ahref__site-audit-page-explorer","mcp__claude_ai_Ahref__site-audit-projects","mcp__claude_ai_Ahref__site-explorer-all-backlinks","mcp__claude_ai_Ahref__site-explorer-anchors","mcp__claude_ai_Ahref__site-explorer-backlinks-stats","mcp__claude_ai_Ahref__site-explorer-broken-backlinks","mcp__claude_ai_Ahref__site-explorer-crawled-pages","mcp__claude_ai_Ahref__site-explorer-domain-rating","mcp__claude_ai_Ahref__site-explorer-domain-rating-history","mcp__claude_ai_Ahref__site-explorer-keywords-history","mcp__claude_ai_Ahref__site-explorer-linked-anchors-external","mcp__claude_ai_Ahref__site-explorer-linked-anchors-internal","mcp__claude_ai_Ahref__site-explorer-linked-domains","mcp__claude_ai_Ahref__site-explorer-metrics","mcp__claude_ai_Ahref__site-explorer-metrics-by-country","mcp__claude_ai_Ahref__site-explorer-metrics-history","mcp__claude_ai_Ahref__site-explorer-organic-competitors","mcp__claude_ai_Ahref__site-explorer-organic-keywords","mcp__claude_ai_Ahref__site-explorer-outlinks-stats","mcp__claude_ai_Ahref__site-explorer-pages-by-backlinks","mcp__claude_ai_Ahref__site-explorer-pages-by-internal-links","mcp__claude_ai_Ahref__site-explorer-pages-by-traffic","mcp__claude_ai_Ahref__site-explorer-pages-history","mcp__claude_ai_Ahref__site-explorer-paid-pages","mcp__claude_ai_Ahref__site-explorer-refdomains-history","mcp__claude_ai_Ahref__site-explorer-referring-domains","mcp__claude_ai_Ahref__site-explorer-top-pages","mcp__claude_ai_Ahref__site-explorer-total-search-volume-history","mcp__claude_ai_Ahref__site-explorer-url-rating-history","mcp__claude_ai_Ahref__social-media-activity-history","mcp__claude_ai_Ahref__social-media-authors","mcp__claude_ai_Ahref__social-media-channel-metrics","mcp__claude_ai_Ahref__social-media-channels","mcp__claude_ai_Ahref__social-media-post-metrics","mcp__claude_ai_Ahref__social-media-posts","mcp__claude_ai_Ahref__subscription-info-limits-and-usage","mcp__claude_ai_Ahref__web-analytics-browser-versions","mcp__claude_ai_Ahref__web-analytics-browser-versions-chart","mcp__claude_ai_Ahref__web-analytics-browsers","mcp__claude_ai_Ahref__web-analytics-browsers-chart","mcp__claude_ai_Ahref__web-analytics-chart","mcp__claude_ai_Ahref__web-analytics-cities","mcp__claude_ai_Ahref__web-analytics-cities-chart","mcp__claude_ai_Ahref__web-analytics-continents","mcp__claude_ai_Ahref__web-analytics-continents-chart","mcp__claude_ai_Ahref__web-analytics-countries","mcp__claude_ai_Ahref__web-analytics-countries-chart","mcp__claude_ai_Ahref__web-analytics-devices","mcp__claude_ai_Ahref__web-analytics-devices-chart","mcp__claude_ai_Ahref__web-analytics-entry-pages","mcp__claude_ai_Ahref__web-analytics-entry-pages-chart","mcp__claude_ai_Ahref__web-analytics-exit-pages","mcp__claude_ai_Ahref__web-analytics-exit-pages-chart","mcp__claude_ai_Ahref__web-analytics-languages","mcp__claude_ai_Ahref__web-analytics-languages-chart","mcp__claude_ai_Ahref__web-analytics-operating-systems","mcp__claude_ai_Ahref__web-analytics-operating-systems-chart","mcp__claude_ai_Ahref__web-analytics-operating-systems-versions","mcp__claude_ai_Ahref__web-analytics-operating-systems-versions-chart","mcp__claude_ai_Ahref__web-analytics-referrers","mcp__claude_ai_Ahref__web-analytics-referrers-chart","mcp__claude_ai_Ahref__web-analytics-source-channels","mcp__claude_ai_Ahref__web-analytics-source-channels-chart","mcp__claude_ai_Ahref__web-analytics-sources","mcp__claude_ai_Ahref__web-analytics-sources-chart","mcp__claude_ai_Ahref__web-analytics-stats","mcp__claude_ai_Ahref__web-analytics-top-pages","mcp__claude_ai_Ahref__web-analytics-top-pages-chart","mcp__claude_ai_Ahref__web-analytics-utm-params","mcp__claude_ai_Ahref__web-analytics-utm-params-chart","mcp__claude_ai_Canva__cancel-editing-transaction","mcp__claude_ai_Canva__comment-on-design","mcp__claude_ai_Canva__commit-editing-transaction","mcp__claude_ai_Canva__copy-design","mcp__claude_ai_Canva__create-design-from-brand-template","mcp__claude_ai_Canva__create-design-from-candidate","mcp__claude_ai_Canva__create-folder","mcp__claude_ai_Canva__export-design","mcp__claude_ai_Canva__generate-design","mcp__claude_ai_Canva__generate-design-structured","mcp__claude_ai_Canva__get-assets","mcp__claude_ai_Canva__get-brand-template-dataset","mcp__claude_ai_Canva__get-design","mcp__claude_ai_Canva__get-design-content","mcp__claude_ai_Canva__get-design-pages","mcp__claude_ai_Canva__get-design-thumbnail","mcp__claude_ai_Canva__get-export-formats","mcp__claude_ai_Canva__get-presenter-notes","mcp__claude_ai_Canva__help","mcp__claude_ai_Canva__import-design-from-url","mcp__claude_ai_Canva__list-brand-kits","mcp__claude_ai_Canva__list-comments","mcp__claude_ai_Canva__list-folder-items","mcp__claude_ai_Canva__list-replies","mcp__claude_ai_Canva__merge-designs","mcp__claude_ai_Canva__move-item-to-folder","mcp__claude_ai_Canva__perform-editing-operations","mcp__claude_ai_Canva__publish-brand-template","mcp__claude_ai_Canva__reply-to-comment","mcp__claude_ai_Canva__request-outline-review","mcp__claude_ai_Canva__resize-design","mcp__claude_ai_Canva__resolve-shortlink","mcp__claude_ai_Canva__search-brand-templates","mcp__claude_ai_Canva__search-designs","mcp__claude_ai_Canva__search-folders","mcp__claude_ai_Canva__start-editing-transaction","mcp__claude_ai_Canva__upload-asset-from-url","mcp__claude_ai_DATA_GOUV_FR__get_dataservice_info","mcp__claude_ai_DATA_GOUV_FR__get_dataservice_openapi_spec","mcp__claude_ai_DATA_GOUV_FR__get_dataset_info","mcp__claude_ai_DATA_GOUV_FR__get_metrics","mcp__claude_ai_DATA_GOUV_FR__get_resource_info","mcp__claude_ai_DATA_GOUV_FR__list_dataset_resources","mcp__claude_ai_DATA_GOUV_FR__query_resource_data","mcp__claude_ai_DATA_GOUV_FR__search_dataservices","mcp__claude_ai_DATA_GOUV_FR__search_datasets","mcp__claude_ai_DATA_GOUV_FR__search_organizations","mcp__claude_ai_Data_For_SEO__authenticate","mcp__claude_ai_Data_For_SEO__complete_authentication","mcp__claude_ai_Esteworld-Body__add_block","mcp__claude_ai_Esteworld-Body__delete_block","mcp__claude_ai_Esteworld-Body__find_esteworld_page","mcp__claude_ai_Esteworld-Body__fix_global_blocks","mcp__claude_ai_Esteworld-Body__get_block","mcp__claude_ai_Esteworld-Body__get_blocks_library","mcp__claude_ai_Esteworld-Body__get_breadcrumb","mcp__claude_ai_Esteworld-Body__get_fr_en_mapping","mcp__claude_ai_Esteworld-Body__get_internal_links","mcp__claude_ai_Esteworld-Body__get_internal_links_en","mcp__claude_ai_Esteworld-Body__get_maillage_rules","mcp__claude_ai_Esteworld-Body__get_page","mcp__claude_ai_Esteworld-Body__get_page_json","mcp__claude_ai_Esteworld-Body__get_page_status","mcp__claude_ai_Esteworld-Body__get_redirections","mcp__claude_ai_Esteworld-Body__get_section_content","mcp__claude_ai_Esteworld-Body__get_thematique_pages","mcp__claude_ai_Esteworld-Body__get_translation_languages","mcp__claude_ai_Esteworld-Body__list_pages","mcp__claude_ai_Esteworld-Body__list_pages_by_thematique","mcp__claude_ai_Esteworld-Body__list_pages_by_type","mcp__claude_ai_Esteworld-Body__list_pages_to_create","mcp__claude_ai_Esteworld-Body__list_pages_to_rewrite","mcp__claude_ai_Esteworld-Body__list_pages_with_esteworld","mcp__claude_ai_Esteworld-Body__list_pages_without_esteworld","mcp__claude_ai_Esteworld-Body__n8n_activate_workflow","mcp__claude_ai_Esteworld-Body__n8n_get_executions","mcp__claude_ai_Esteworld-Body__n8n_get_workflow","mcp__claude_ai_Esteworld-Body__n8n_list_workflows","mcp__claude_ai_Esteworld-Body__n8n_trigger_webhook","mcp__claude_ai_Esteworld-Body__preview_global_fixes","mcp__claude_ai_Esteworld-Body__reorder_blocks","mcp__claude_ai_Esteworld-Body__search_content","mcp__claude_ai_Esteworld-Body__search_links_by_keyword","mcp__claude_ai_Esteworld-Body__search_links_by_keyword_en","mcp__claude_ai_Esteworld-Body__submit_page","mcp__claude_ai_Esteworld-Body__submit_page_light","mcp__claude_ai_Esteworld-Body__translate_page","mcp__claude_ai_Esteworld-Body__update_block","mcp__claude_ai_Figma__add_code_connect_map","mcp__claude_ai_Figma__create_new_file","mcp__claude_ai_Figma__generate_diagram","mcp__claude_ai_Figma__get_code_connect_map","mcp__claude_ai_Figma__get_code_connect_suggestions","mcp__claude_ai_Figma__get_context_for_code_connect","mcp__claude_ai_Figma__get_design_context","mcp__claude_ai_Figma__get_figjam","mcp__claude_ai_Figma__get_libraries","mcp__claude_ai_Figma__get_metadata","mcp__claude_ai_Figma__get_screenshot","mcp__claude_ai_Figma__get_variable_defs","mcp__claude_ai_Figma__search_design_system","mcp__claude_ai_Figma__send_code_connect_mappings","mcp__claude_ai_Figma__upload_assets","mcp__claude_ai_Figma__use_figma","mcp__claude_ai_Figma__whoami","mcp__claude_ai_Gmail__create_draft","mcp__claude_ai_Gmail__create_label","mcp__claude_ai_Gmail__delete_label","mcp__claude_ai_Gmail__get_thread","mcp__claude_ai_Gmail__label_message","mcp__claude_ai_Gmail__label_thread","mcp__claude_ai_Gmail__list_drafts","mcp__claude_ai_Gmail__list_labels","mcp__claude_ai_Gmail__search_threads","mcp__claude_ai_Gmail__unlabel_message","mcp__claude_ai_Gmail__unlabel_thread","mcp__claude_ai_Gmail__update_label","mcp__claude_ai_Google_Calendar__create_event","mcp__claude_ai_Google_Calendar__delete_event","mcp__claude_ai_Google_Calendar__get_event","mcp__claude_ai_Google_Calendar__list_calendars","mcp__claude_ai_Google_Calendar__list_events","mcp__claude_ai_Google_Calendar__respond_to_event","mcp__claude_ai_Google_Calendar__suggest_time","mcp__claude_ai_Google_Calendar__update_event","mcp__claude_ai_Google_Drive__copy_file","mcp__claude_ai_Google_Drive__create_file","mcp__claude_ai_Google_Drive__download_file_content","mcp__claude_ai_Google_Drive__get_file_metadata","mcp__claude_ai_Google_Drive__get_file_permissions","mcp__claude_ai_Google_Drive__list_recent_files","mcp__claude_ai_Google_Drive__read_file_content","mcp__claude_ai_Google_Drive__search_files","mcp__claude_ai_SEMRush__backlink_research","mcp__claude_ai_SEMRush__execute_report","mcp__claude_ai_SEMRush__get_report_schema","mcp__claude_ai_SEMRush__keyword_research","mcp__claude_ai_SEMRush__organic_research","mcp__claude_ai_SEMRush__overview_research","mcp__claude_ai_SEMRush__projects_research","mcp__claude_ai_SEMRush__siteaudit_research","mcp__claude_ai_SEMRush__subdomain_research","mcp__claude_ai_SEMRush__subfolder_research","mcp__claude_ai_SEMRush__tracking_research","mcp__claude_ai_SEMRush__trends_research","mcp__claude_ai_SEMRush__url_research","mcp__claude_ai_Vercel__add_toolbar_reaction","mcp__claude_ai_Vercel__change_toolbar_thread_resolve_status","mcp__claude_ai_Vercel__check_domain_availability_and_price","mcp__claude_ai_Vercel__deploy_to_vercel","mcp__claude_ai_Vercel__edit_toolbar_message","mcp__claude_ai_Vercel__get_access_to_vercel_url","mcp__claude_ai_Vercel__get_deployment","mcp__claude_ai_Vercel__get_deployment_build_logs","mcp__claude_ai_Vercel__get_project","mcp__claude_ai_Vercel__get_runtime_logs","mcp__claude_ai_Vercel__get_toolbar_thread","mcp__claude_ai_Vercel__list_deployments","mcp__claude_ai_Vercel__list_projects","mcp__claude_ai_Vercel__list_teams","mcp__claude_ai_Vercel__list_toolbar_threads","mcp__claude_ai_Vercel__reply_to_toolbar_thread","mcp__claude_ai_Vercel__search_vercel_documentation","mcp__claude_ai_Vercel__web_fetch_vercel_url","mcp__gpt-image-2__continue_edit_session","mcp__gpt-image-2__edit_image","mcp__gpt-image-2__end_edit_session","mcp__gpt-image-2__generate_image","mcp__gpt-image-2__list_edit_sessions","mcp__gpt-image-2__start_edit_session","mcp__hostinger__DNS_deleteDNSRecordsV1","mcp__hostinger__DNS_getDNSRecordsV1","mcp__hostinger__DNS_getDNSSnapshotListV1","mcp__hostinger__DNS_getDNSSnapshotV1","mcp__hostinger__DNS_resetDNSRecordsV1","mcp__hostinger__DNS_restoreDNSSnapshotV1","mcp__hostinger__DNS_updateDNSRecordsV1","mcp__hostinger__DNS_validateDNSRecordsV1","mcp__hostinger__VPS_activateFirewallV1","mcp__hostinger__VPS_attachPublicKeyV1","mcp__hostinger__VPS_createFirewallRuleV1","mcp__hostinger__VPS_createNewFirewallV1","mcp__hostinger__VPS_createNewProjectV1","mcp__hostinger__VPS_createPTRRecordV1","mcp__hostinger__VPS_createPostInstallScriptV1","mcp__hostinger__VPS_createPublicKeyV1","mcp__hostinger__VPS_createSnapshotV1","mcp__hostinger__VPS_deactivateFirewallV1","mcp__hostinger__VPS_deleteFirewallRuleV1","mcp__hostinger__VPS_deleteFirewallV1","mcp__hostinger__VPS_deletePTRRecordV1","mcp__hostinger__VPS_deletePostInstallScriptV1","mcp__hostinger__VPS_deleteProjectV1","mcp__hostinger__VPS_deletePublicKeyV1","mcp__hostinger__VPS_deleteSnapshotV1","mcp__hostinger__VPS_getActionDetailsV1","mcp__hostinger__VPS_getActionsV1","mcp__hostinger__VPS_getAttachedPublicKeysV1","mcp__hostinger__VPS_getBackupsV1","mcp__hostinger__VPS_getDataCenterListV1","mcp__hostinger__VPS_getFirewallDetailsV1","mcp__hostinger__VPS_getFirewallListV1","mcp__hostinger__VPS_getMetricsV1","mcp__hostinger__VPS_getPostInstallScriptV1","mcp__hostinger__VPS_getPostInstallScriptsV1","mcp__hostinger__VPS_getProjectContainersV1","mcp__hostinger__VPS_getProjectContentsV1","mcp__hostinger__VPS_getProjectListV1","mcp__hostinger__VPS_getProjectLogsV1","mcp__hostinger__VPS_getPublicKeysV1","mcp__hostinger__VPS_getScanMetricsV1","mcp__hostinger__VPS_getSnapshotV1","mcp__hostinger__VPS_getTemplateDetailsV1","mcp__hostinger__VPS_getTemplatesV1","mcp__hostinger__VPS_getVirtualMachineDetailsV1","mcp__hostinger__VPS_getVirtualMachinesV1","mcp__hostinger__VPS_installMonarxV1","mcp__hostinger__VPS_purchaseNewVirtualMachineV1","mcp__hostinger__VPS_recreateVirtualMachineV1","mcp__hostinger__VPS_resetHostnameV1","mcp__hostinger__VPS_restartProjectV1","mcp__hostinger__VPS_restartVirtualMachineV1","mcp__hostinger__VPS_restoreBackupV1","mcp__hostinger__VPS_restoreSnapshotV1","mcp__hostinger__VPS_setHostnameV1","mcp__hostinger__VPS_setNameserversV1","mcp__hostinger__VPS_setPanelPasswordV1","mcp__hostinger__VPS_setRootPasswordV1","mcp__hostinger__VPS_setupPurchasedVirtualMachineV1","mcp__hostinger__VPS_startProjectV1","mcp__hostinger__VPS_startRecoveryModeV1","mcp__hostinger__VPS_startVirtualMachineV1","mcp__hostinger__VPS_stopProjectV1","mcp__hostinger__VPS_stopRecoveryModeV1","mcp__hostinger__VPS_stopVirtualMachineV1","mcp__hostinger__VPS_syncFirewallV1","mcp__hostinger__VPS_uninstallMonarxV1","mcp__hostinger__VPS_updateFirewallRuleV1","mcp__hostinger__VPS_updatePostInstallScriptV1","mcp__hostinger__VPS_updateProjectV1","mcp__hostinger__billing_deletePaymentMethodV1","mcp__hostinger__billing_disableAutoRenewalV1","mcp__hostinger__billing_enableAutoRenewalV1","mcp__hostinger__billing_getCatalogItemListV1","mcp__hostinger__billing_getPaymentMethodListV1","mcp__hostinger__billing_getSubscriptionListV1","mcp__hostinger__billing_setDefaultPaymentMethodV1","mcp__hostinger__domains_checkDomainAvailabilityV1","mcp__hostinger__domains_createDomainForwardingV1","mcp__hostinger__domains_createWHOISProfileV1","mcp__hostinger__domains_deleteDomainForwardingV1","mcp__hostinger__domains_deleteWHOISProfileV1","mcp__hostinger__domains_disableDomainLockV1","mcp__hostinger__domains_disablePrivacyProtectionV1","mcp__hostinger__domains_enableDomainLockV1","mcp__hostinger__domains_enablePrivacyProtectionV1","mcp__hostinger__domains_getDomainDetailsV1","mcp__hostinger__domains_getDomainForwardingV1","mcp__hostinger__domains_getDomainListV1","mcp__hostinger__domains_getWHOISProfileListV1","mcp__hostinger__domains_getWHOISProfileUsageV1","mcp__hostinger__domains_getWHOISProfileV1","mcp__hostinger__domains_purchaseNewDomainV1","mcp__hostinger__domains_updateDomainNameserversV1","mcp__hostinger__hosting_createWebsiteV1","mcp__hostinger__hosting_deployJsApplication","mcp__hostinger__hosting_deployStaticWebsite","mcp__hostinger__hosting_deployWordpressPlugin","mcp__hostinger__hosting_deployWordpressTheme","mcp__hostinger__hosting_generateAFreeSubdomainV1","mcp__hostinger__hosting_importWordpressWebsite","mcp__hostinger__hosting_listAvailableDatacentersV1","mcp__hostinger__hosting_listJsDeployments","mcp__hostinger__hosting_listOrdersV1","mcp__hostinger__hosting_listWebsitesV1","mcp__hostinger__hosting_showJsDeploymentLogs","mcp__hostinger__hosting_verifyDomainOwnershipV1","mcp__hostinger__reach_createANewContactSegmentV1","mcp__hostinger__reach_createANewContactV1","mcp__hostinger__reach_createNewContactsV1","mcp__hostinger__reach_deleteAContactV1","mcp__hostinger__reach_getSegmentDetailsV1","mcp__hostinger__reach_listContactGroupsV1","mcp__hostinger__reach_listContactsV1","mcp__hostinger__reach_listProfilesV1","mcp__hostinger__reach_listSegmentContactsV1","mcp__hostinger__reach_listSegmentsV1","mcp__hostinger__v2_getDomainVerificationsDIRECT","mcp__nanobanana__generate_image","mcp__nanobanana__maintenance","mcp__nanobanana__show_output_stats","mcp__nanobanana__upload_file","mcp__plugin_vercel_vercel__authenticate","mcp__plugin_vercel_vercel__complete_authentication","mcp__refero__refero_get_flow","mcp__refero__refero_get_screen","mcp__refero__refero_get_screen_image","mcp__refero__refero_get_similar_screens","mcp__refero__refero_get_style","mcp__refero__refero_search_flows","mcp__refero__refero_search_screens","mcp__refero__refero_search_styles","mcp__semrush__authenticate","mcp__semrush__complete_authentication","mcp__stock-images-mcp__search_stock_images","mcp__trello__add_card_to_list","mcp__trello__add_checklist_item","mcp__trello__add_comment","mcp__trello__add_list_to_board","mcp__trello__archive_card","mcp__trello__archive_list","mcp__trello__assign_member_to_card","mcp__trello__attach_file_to_card","mcp__trello__attach_image_data_to_card","mcp__trello__attach_image_to_card","mcp__trello__create_board","mcp__trello__create_checklist","mcp__trello__create_label","mcp__trello__delete_comment","mcp__trello__delete_label","mcp__trello__find_checklist_items_by_description","mcp__trello__get_acceptance_criteria","mcp__trello__get_active_board_info","mcp__trello__get_board_labels","mcp__trello__get_board_members","mcp__trello__get_card","mcp__trello__get_card_comments","mcp__trello__get_card_history","mcp__trello__get_cards_by_list_id","mcp__trello__get_checklist_by_name","mcp__trello__get_checklist_items","mcp__trello__get_health","mcp__trello__get_health_detailed","mcp__trello__get_health_metadata","mcp__trello__get_health_performance","mcp__trello__get_lists","mcp__trello__get_my_cards","mcp__trello__get_recent_activity","mcp__trello__list_boards","mcp__trello__list_boards_in_workspace","mcp__trello__list_workspaces","mcp__trello__move_card","mcp__trello__perform_system_repair","mcp__trello__remove_member_from_card","mcp__trello__set_active_board","mcp__trello__set_active_workspace","mcp__trello__update_card_details","mcp__trello__update_checklist_item","mcp__trello__update_comment","mcp__trello__update_label"],"addedLines":["CronCreate","CronDelete","CronList","EnterWorktree","ExitWorktree","ListMcpResourcesTool","Monitor","NotebookEdit","PushNotification","ReadMcpResourceTool","RemoteTrigger","TaskCreate","TaskGet","TaskList","TaskStop","TaskUpdate","WebFetch","WebSearch","mcp__EstimanouContent__add_article_block","mcp__EstimanouContent__add_block","mcp__EstimanouContent__create_article","mcp__EstimanouContent__create_page","mcp__EstimanouContent__delete_article","mcp__EstimanouContent__delete_article_block","mcp__EstimanouContent__delete_block","mcp__EstimanouContent__get_article","mcp__EstimanouContent__get_city_page","mcp__EstimanouContent__get_page","mcp__EstimanouContent__list_articles","mcp__EstimanouContent__list_available_blocks","mcp__EstimanouContent__list_city_pages","mcp__EstimanouContent__list_pages","mcp__EstimanouContent__list_site_urls","mcp__EstimanouContent__reorder_article_blocks","mcp__EstimanouContent__reorder_blocks","mcp__EstimanouContent__replace_article_content","mcp__EstimanouContent__replace_city_seo_content","mcp__EstimanouContent__replace_page_layout","mcp__EstimanouContent__search_internal_links","mcp__EstimanouContent__update_article","mcp__EstimanouContent__update_article_block","mcp__EstimanouContent__update_block","mcp__EstimanouContent__update_city_page_content","mcp__claude_ai_Ahref__batch-analysis","mcp__claude_ai_Ahref__brand-radar-ai-responses","mcp__claude_ai_Ahref__brand-radar-ai-responses-entities","mcp__claude_ai_Ahref__brand-radar-cited-domains","mcp__claude_ai_Ahref__brand-radar-cited-domains-entities","mcp__claude_ai_Ahref__brand-radar-cited-pages","mcp__claude_ai_Ahref__brand-radar-cited-pages-entities","mcp__claude_ai_Ahref__brand-radar-impressions-history","mcp__claude_ai_Ahref__brand-radar-impressions-history-entities","mcp__claude_ai_Ahref__brand-radar-impressions-overview","mcp__claude_ai_Ahref__brand-radar-impressions-overview-entities","mcp__claude_ai_Ahref__brand-radar-mentions-history","mcp__claude_ai_Ahref__brand-radar-mentions-history-entities","mcp__claude_ai_Ahref__brand-radar-mentions-overview","mcp__claude_ai_Ahref__brand-radar-mentions-overview-entities","mcp__claude_ai_Ahref__brand-radar-sov-history","mcp__claude_ai_Ahref__brand-radar-sov-history-entities","mcp__claude_ai_Ahref__brand-radar-sov-overview","mcp__claude_ai_Ahref__brand-radar-sov-overview-entities","mcp__claude_ai_Ahref__doc","mcp__claude_ai_Ahref__gsc-anonymous-queries","mcp__claude_ai_Ahref__gsc-ctr-by-position","mcp__claude_ai_Ahref__gsc-keyword-history","mcp__claude_ai_Ahref__gsc-keywords","mcp__claude_ai_Ahref__gsc-metrics-by-country","mcp__claude_ai_Ahref__gsc-page-history","mcp__claude_ai_Ahref__gsc-pages","mcp__claude_ai_Ahref__gsc-pages-history","mcp__claude_ai_Ahref__gsc-performance-by-device","mcp__claude_ai_Ahref__gsc-performance-by-position","mcp__claude_ai_Ahref__gsc-performance-history","mcp__claude_ai_Ahref__gsc-positions-history","mcp__claude_ai_Ahref__keywords-explorer-matching-terms","mcp__claude_ai_Ahref__keywords-explorer-overview","mcp__claude_ai_Ahref__keywords-explorer-related-terms","mcp__claude_ai_Ahref__keywords-explorer-search-suggestions","mcp__claude_ai_Ahref__keywords-explorer-volume-by-country","mcp__claude_ai_Ahref__keywords-explorer-volume-history","mcp__claude_ai_Ahref__management-brand-radar-prompts","mcp__claude_ai_Ahref__management-brand-radar-reports","mcp__claude_ai_Ahref__management-keyword-list-keywords","mcp__claude_ai_Ahref__management-locations","mcp__claude_ai_Ahref__management-project-competitors","mcp__claude_ai_Ahref__management-project-keywords","mcp__claude_ai_Ahref__management-projects","mcp__claude_ai_Ahref__public-crawler-ip-ranges","mcp__claude_ai_Ahref__public-crawler-ips","mcp__claude_ai_Ahref__rank-tracker-competitors-domains","mcp__claude_ai_Ahref__rank-tracker-competitors-overview","mcp__claude_ai_Ahref__rank-tracker-competitors-pages","mcp__claude_ai_Ahref__rank-tracker-competitors-stats","mcp__claude_ai_Ahref__rank-tracker-overview","mcp__claude_ai_Ahref__rank-tracker-serp-overview","mcp__claude_ai_Ahref__render-data-table","mcp__claude_ai_Ahref__render-scorecard","mcp__claude_ai_Ahref__render-time-series-chart","mcp__claude_ai_Ahref__serp-overview","mcp__claude_ai_Ahref__site-audit-issues","mcp__claude_ai_Ahref__site-audit-page-content","mcp__claude_ai_Ahref__site-audit-page-explorer","mcp__claude_ai_Ahref__site-audit-projects","mcp__claude_ai_Ahref__site-explorer-all-backlinks","mcp__claude_ai_Ahref__site-explorer-anchors","mcp__claude_ai_Ahref__site-explorer-backlinks-stats","mcp__claude_ai_Ahref__site-explorer-broken-backlinks","mcp__claude_ai_Ahref__site-explorer-crawled-pages","mcp__claude_ai_Ahref__site-explorer-domain-rating","mcp__claude_ai_Ahref__site-explorer-domain-rating-history","mcp__claude_ai_Ahref__site-explorer-keywords-history","mcp__claude_ai_Ahref__site-explorer-linked-anchors-external","mcp__claude_ai_Ahref__site-explorer-linked-anchors-internal","mcp__claude_ai_Ahref__site-explorer-linked-domains","mcp__claude_ai_Ahref__site-explorer-metrics","mcp__claude_ai_Ahref__site-explorer-metrics-by-country","mcp__claude_ai_Ahref__site-explorer-metrics-history","mcp__claude_ai_Ahref__site-explorer-organic-competitors","mcp__claude_ai_Ahref__site-explorer-organic-keywords","mcp__claude_ai_Ahref__site-explorer-outlinks-stats","mcp__claude_ai_Ahref__site-explorer-pages-by-backlinks","mcp__claude_ai_Ahref__site-explorer-pages-by-internal-links","mcp__claude_ai_Ahref__site-explorer-pages-by-traffic","mcp__claude_ai_Ahref__site-explorer-pages-history","mcp__claude_ai_Ahref__site-explorer-paid-pages","mcp__claude_ai_Ahref__site-explorer-refdomains-history","mcp__claude_ai_Ahref__site-explorer-referring-domains","mcp__claude_ai_Ahref__site-explorer-top-pages","mcp__claude_ai_Ahref__site-explorer-total-search-volume-history","mcp__claude_ai_Ahref__site-explorer-url-rating-history","mcp__claude_ai_Ahref__social-media-activity-history","mcp__claude_ai_Ahref__social-media-authors","mcp__claude_ai_Ahref__social-media-channel-metrics","mcp__claude_ai_Ahref__social-media-channels","mcp__claude_ai_Ahref__social-media-post-metrics","mcp__claude_ai_Ahref__social-media-posts","mcp__claude_ai_Ahref__subscription-info-limits-and-usage","mcp__claude_ai_Ahref__web-analytics-browser-versions","mcp__claude_ai_Ahref__web-analytics-browser-versions-chart","mcp__claude_ai_Ahref__web-analytics-browsers","mcp__claude_ai_Ahref__web-analytics-browsers-chart","mcp__claude_ai_Ahref__web-analytics-chart","mcp__claude_ai_Ahref__web-analytics-cities","mcp__claude_ai_Ahref__web-analytics-cities-chart","mcp__claude_ai_Ahref__web-analytics-continents","mcp__claude_ai_Ahref__web-analytics-continents-chart","mcp__claude_ai_Ahref__web-analytics-countries","mcp__claude_ai_Ahref__web-analytics-countries-chart","mcp__claude_ai_Ahref__web-analytics-devices","mcp__claude_ai_Ahref__web-analytics-devices-chart","mcp__claude_ai_Ahref__web-analytics-entry-pages","mcp__claude_ai_Ahref__web-analytics-entry-pages-chart","mcp__claude_ai_Ahref__web-analytics-exit-pages","mcp__claude_ai_Ahref__web-analytics-exit-pages-chart","mcp__claude_ai_Ahref__web-analytics-languages","mcp__claude_ai_Ahref__web-analytics-languages-chart","mcp__claude_ai_Ahref__web-analytics-operating-systems","mcp__claude_ai_Ahref__web-analytics-operating-systems-chart","mcp__claude_ai_Ahref__web-analytics-operating-systems-versions","mcp__claude_ai_Ahref__web-analytics-operating-systems-versions-chart","mcp__claude_ai_Ahref__web-analytics-referrers","mcp__claude_ai_Ahref__web-analytics-referrers-chart","mcp__claude_ai_Ahref__web-analytics-source-channels","mcp__claude_ai_Ahref__web-analytics-source-channels-chart","mcp__claude_ai_Ahref__web-analytics-sources","mcp__claude_ai_Ahref__web-analytics-sources-chart","mcp__claude_ai_Ahref__web-analytics-stats","mcp__claude_ai_Ahref__web-analytics-top-pages","mcp__claude_ai_Ahref__web-analytics-top-pages-chart","mcp__claude_ai_Ahref__web-analytics-utm-params","mcp__claude_ai_Ahref__web-analytics-utm-params-chart","mcp__claude_ai_Canva__cancel-editing-transaction","mcp__claude_ai_Canva__comment-on-design","mcp__claude_ai_Canva__commit-editing-transaction","mcp__claude_ai_Canva__copy-design","mcp__claude_ai_Canva__create-design-from-brand-template","mcp__claude_ai_Canva__create-design-from-candidate","mcp__claude_ai_Canva__create-folder","mcp__claude_ai_Canva__export-design","mcp__claude_ai_Canva__generate-design","mcp__claude_ai_Canva__generate-design-structured","mcp__claude_ai_Canva__get-assets","mcp__claude_ai_Canva__get-brand-template-dataset","mcp__claude_ai_Canva__get-design","mcp__claude_ai_Canva__get-design-content","mcp__claude_ai_Canva__get-design-pages","mcp__claude_ai_Canva__get-design-thumbnail","mcp__claude_ai_Canva__get-export-formats","mcp__claude_ai_Canva__get-presenter-notes","mcp__claude_ai_Canva__help","mcp__claude_ai_Canva__import-design-from-url","mcp__claude_ai_Canva__list-brand-kits","mcp__claude_ai_Canva__list-comments","mcp__claude_ai_Canva__list-folder-items","mcp__claude_ai_Canva__list-replies","mcp__claude_ai_Canva__merge-designs","mcp__claude_ai_Canva__move-item-to-folder","mcp__claude_ai_Canva__perform-editing-operations","mcp__claude_ai_Canva__publish-brand-template","mcp__claude_ai_Canva__reply-to-comment","mcp__claude_ai_Canva__request-outline-review","mcp__claude_ai_Canva__resize-design","mcp__claude_ai_Canva__resolve-shortlink","mcp__claude_ai_Canva__search-brand-templates","mcp__claude_ai_Canva__search-designs","mcp__claude_ai_Canva__search-folders","mcp__claude_ai_Canva__start-editing-transaction","mcp__claude_ai_Canva__upload-asset-from-url","mcp__claude_ai_DATA_GOUV_FR__get_dataservice_info","mcp__claude_ai_DATA_GOUV_FR__get_dataservice_openapi_spec","mcp__claude_ai_DATA_GOUV_FR__get_dataset_info","mcp__claude_ai_DATA_GOUV_FR__get_metrics","mcp__claude_ai_DATA_GOUV_FR__get_resource_info","mcp__claude_ai_DATA_GOUV_FR__list_dataset_resources","mcp__claude_ai_DATA_GOUV_FR__query_resource_data","mcp__claude_ai_DATA_GOUV_FR__search_dataservices","mcp__claude_ai_DATA_GOUV_FR__search_datasets","mcp__claude_ai_DATA_GOUV_FR__search_organizations","mcp__claude_ai_Data_For_SEO__authenticate","mcp__claude_ai_Data_For_SEO__complete_authentication","mcp__claude_ai_Esteworld-Body__add_block","mcp__claude_ai_Esteworld-Body__delete_block","mcp__claude_ai_Esteworld-Body__find_esteworld_page","mcp__claude_ai_Esteworld-Body__fix_global_blocks","mcp__claude_ai_Esteworld-Body__get_block","mcp__claude_ai_Esteworld-Body__get_blocks_library","mcp__claude_ai_Esteworld-Body__get_breadcrumb","mcp__claude_ai_Esteworld-Body__get_fr_en_mapping","mcp__claude_ai_Esteworld-Body__get_internal_links","mcp__claude_ai_Esteworld-Body__get_internal_links_en","mcp__claude_ai_Esteworld-Body__get_maillage_rules","mcp__claude_ai_Esteworld-Body__get_page","mcp__claude_ai_Esteworld-Body__get_page_json","mcp__claude_ai_Esteworld-Body__get_page_status","mcp__claude_ai_Esteworld-Body__get_redirections","mcp__claude_ai_Esteworld-Body__get_section_content","mcp__claude_ai_Esteworld-Body__get_thematique_pages","mcp__claude_ai_Esteworld-Body__get_translation_languages","mcp__claude_ai_Esteworld-Body__list_pages","mcp__claude_ai_Esteworld-Body__list_pages_by_thematique","mcp__claude_ai_Esteworld-Body__list_pages_by_type","mcp__claude_ai_Esteworld-Body__list_pages_to_create","mcp__claude_ai_Esteworld-Body__list_pages_to_rewrite","mcp__claude_ai_Esteworld-Body__list_pages_with_esteworld","mcp__claude_ai_Esteworld-Body__list_pages_without_esteworld","mcp__claude_ai_Esteworld-Body__n8n_activate_workflow","mcp__claude_ai_Esteworld-Body__n8n_get_executions","mcp__claude_ai_Esteworld-Body__n8n_get_workflow","mcp__claude_ai_Esteworld-Body__n8n_list_workflows","mcp__claude_ai_Esteworld-Body__n8n_trigger_webhook","mcp__claude_ai_Esteworld-Body__preview_global_fixes","mcp__claude_ai_Esteworld-Body__reorder_blocks","mcp__claude_ai_Esteworld-Body__search_content","mcp__claude_ai_Esteworld-Body__search_links_by_keyword","mcp__claude_ai_Esteworld-Body__search_links_by_keyword_en","mcp__claude_ai_Esteworld-Body__submit_page","mcp__claude_ai_Esteworld-Body__submit_page_light","mcp__claude_ai_Esteworld-Body__translate_page","mcp__claude_ai_Esteworld-Body__update_block","mcp__claude_ai_Figma__add_code_connect_map","mcp__claude_ai_Figma__create_new_file","mcp__claude_ai_Figma__generate_diagram","mcp__claude_ai_Figma__get_code_connect_map","mcp__claude_ai_Figma__get_code_connect_suggestions","mcp__claude_ai_Figma__get_context_for_code_connect","mcp__claude_ai_Figma__get_design_context","mcp__claude_ai_Figma__get_figjam","mcp__claude_ai_Figma__get_libraries","mcp__claude_ai_Figma__get_metadata","mcp__claude_ai_Figma__get_screenshot","mcp__claude_ai_Figma__get_variable_defs","mcp__claude_ai_Figma__search_design_system","mcp__claude_ai_Figma__send_code_connect_mappings","mcp__claude_ai_Figma__upload_assets","mcp__claude_ai_Figma__use_figma","mcp__claude_ai_Figma__whoami","mcp__claude_ai_Gmail__create_draft","mcp__claude_ai_Gmail__create_label","mcp__claude_ai_Gmail__delete_label","mcp__claude_ai_Gmail__get_thread","mcp__claude_ai_Gmail__label_message","mcp__claude_ai_Gmail__label_thread","mcp__claude_ai_Gmail__list_drafts","mcp__claude_ai_Gmail__list_labels","mcp__claude_ai_Gmail__search_threads","mcp__claude_ai_Gmail__unlabel_message","mcp__claude_ai_Gmail__unlabel_thread","mcp__claude_ai_Gmail__update_label","mcp__claude_ai_Google_Calendar__create_event","mcp__claude_ai_Google_Calendar__delete_event","mcp__claude_ai_Google_Calendar__get_event","mcp__claude_ai_Google_Calendar__list_calendars","mcp__claude_ai_Google_Calendar__list_events","mcp__claude_ai_Google_Calendar__respond_to_event","mcp__claude_ai_Google_Calendar__suggest_time","mcp__claude_ai_Google_Calendar__update_event","mcp__claude_ai_Google_Drive__copy_file","mcp__claude_ai_Google_Drive__create_file","mcp__claude_ai_Google_Drive__download_file_content","mcp__claude_ai_Google_Drive__get_file_metadata","mcp__claude_ai_Google_Drive__get_file_permissions","mcp__claude_ai_Google_Drive__list_recent_files","mcp__claude_ai_Google_Drive__read_file_content","mcp__claude_ai_Google_Drive__search_files","mcp__claude_ai_SEMRush__backlink_research","mcp__claude_ai_SEMRush__execute_report","mcp__claude_ai_SEMRush__get_report_schema","mcp__claude_ai_SEMRush__keyword_research","mcp__claude_ai_SEMRush__organic_research","mcp__claude_ai_SEMRush__overview_research","mcp__claude_ai_SEMRush__projects_research","mcp__claude_ai_SEMRush__siteaudit_research","mcp__claude_ai_SEMRush__subdomain_research","mcp__claude_ai_SEMRush__subfolder_research","mcp__claude_ai_SEMRush__tracking_research","mcp__claude_ai_SEMRush__trends_research","mcp__claude_ai_SEMRush__url_research","mcp__claude_ai_Vercel__add_toolbar_reaction","mcp__claude_ai_Vercel__change_toolbar_thread_resolve_status","mcp__claude_ai_Vercel__check_domain_availability_and_price","mcp__claude_ai_Vercel__deploy_to_vercel","mcp__claude_ai_Vercel__edit_toolbar_message","mcp__claude_ai_Vercel__get_access_to_vercel_url","mcp__claude_ai_Vercel__get_deployment","mcp__claude_ai_Vercel__get_deployment_build_logs","mcp__claude_ai_Vercel__get_project","mcp__claude_ai_Vercel__get_runtime_logs","mcp__claude_ai_Vercel__get_toolbar_thread","mcp__claude_ai_Vercel__list_deployments","mcp__claude_ai_Vercel__list_projects","mcp__claude_ai_Vercel__list_teams","mcp__claude_ai_Vercel__list_toolbar_threads","mcp__claude_ai_Vercel__reply_to_toolbar_thread","mcp__claude_ai_Vercel__search_vercel_documentation","mcp__claude_ai_Vercel__web_fetch_vercel_url","mcp__gpt-image-2__continue_edit_session","mcp__gpt-image-2__edit_image","mcp__gpt-image-2__end_edit_session","mcp__gpt-image-2__generate_image","mcp__gpt-image-2__list_edit_sessions","mcp__gpt-image-2__start_edit_session","mcp__hostinger__DNS_deleteDNSRecordsV1","mcp__hostinger__DNS_getDNSRecordsV1","mcp__hostinger__DNS_getDNSSnapshotListV1","mcp__hostinger__DNS_getDNSSnapshotV1","mcp__hostinger__DNS_resetDNSRecordsV1","mcp__hostinger__DNS_restoreDNSSnapshotV1","mcp__hostinger__DNS_updateDNSRecordsV1","mcp__hostinger__DNS_validateDNSRecordsV1","mcp__hostinger__VPS_activateFirewallV1","mcp__hostinger__VPS_attachPublicKeyV1","mcp__hostinger__VPS_createFirewallRuleV1","mcp__hostinger__VPS_createNewFirewallV1","mcp__hostinger__VPS_createNewProjectV1","mcp__hostinger__VPS_createPTRRecordV1","mcp__hostinger__VPS_createPostInstallScriptV1","mcp__hostinger__VPS_createPublicKeyV1","mcp__hostinger__VPS_createSnapshotV1","mcp__hostinger__VPS_deactivateFirewallV1","mcp__hostinger__VPS_deleteFirewallRuleV1","mcp__hostinger__VPS_deleteFirewallV1","mcp__hostinger__VPS_deletePTRRecordV1","mcp__hostinger__VPS_deletePostInstallScriptV1","mcp__hostinger__VPS_deleteProjectV1","mcp__hostinger__VPS_deletePublicKeyV1","mcp__hostinger__VPS_deleteSnapshotV1","mcp__hostinger__VPS_getActionDetailsV1","mcp__hostinger__VPS_getActionsV1","mcp__hostinger__VPS_getAttachedPublicKeysV1","mcp__hostinger__VPS_getBackupsV1","mcp__hostinger__VPS_getDataCenterListV1","mcp__hostinger__VPS_getFirewallDetailsV1","mcp__hostinger__VPS_getFirewallListV1","mcp__hostinger__VPS_getMetricsV1","mcp__hostinger__VPS_getPostInstallScriptV1","mcp__hostinger__VPS_getPostInstallScriptsV1","mcp__hostinger__VPS_getProjectContainersV1","mcp__hostinger__VPS_getProjectContentsV1","mcp__hostinger__VPS_getProjectListV1","mcp__hostinger__VPS_getProjectLogsV1","mcp__hostinger__VPS_getPublicKeysV1","mcp__hostinger__VPS_getScanMetricsV1","mcp__hostinger__VPS_getSnapshotV1","mcp__hostinger__VPS_getTemplateDetailsV1","mcp__hostinger__VPS_getTemplatesV1","mcp__hostinger__VPS_getVirtualMachineDetailsV1","mcp__hostinger__VPS_getVirtualMachinesV1","mcp__hostinger__VPS_installMonarxV1","mcp__hostinger__VPS_purchaseNewVirtualMachineV1","mcp__hostinger__VPS_recreateVirtualMachineV1","mcp__hostinger__VPS_resetHostnameV1","mcp__hostinger__VPS_restartProjectV1","mcp__hostinger__VPS_restartVirtualMachineV1","mcp__hostinger__VPS_restoreBackupV1","mcp__hostinger__VPS_restoreSnapshotV1","mcp__hostinger__VPS_setHostnameV1","mcp__hostinger__VPS_setNameserversV1","mcp__hostinger__VPS_setPanelPasswordV1","mcp__hostinger__VPS_setRootPasswordV1","mcp__hostinger__VPS_setupPurchasedVirtualMachineV1","mcp__hostinger__VPS_startProjectV1","mcp__hostinger__VPS_startRecoveryModeV1","mcp__hostinger__VPS_startVirtualMachineV1","mcp__hostinger__VPS_stopProjectV1","mcp__hostinger__VPS_stopRecoveryModeV1","mcp__hostinger__VPS_stopVirtualMachineV1","mcp__hostinger__VPS_syncFirewallV1","mcp__hostinger__VPS_uninstallMonarxV1","mcp__hostinger__VPS_updateFirewallRuleV1","mcp__hostinger__VPS_updatePostInstallScriptV1","mcp__hostinger__VPS_updateProjectV1","mcp__hostinger__billing_deletePaymentMethodV1","mcp__hostinger__billing_disableAutoRenewalV1","mcp__hostinger__billing_enableAutoRenewalV1","mcp__hostinger__billing_getCatalogItemListV1","mcp__hostinger__billing_getPaymentMethodListV1","mcp__hostinger__billing_getSubscriptionListV1","mcp__hostinger__billing_setDefaultPaymentMethodV1","mcp__hostinger__domains_checkDomainAvailabilityV1","mcp__hostinger__domains_createDomainForwardingV1","mcp__hostinger__domains_createWHOISProfileV1","mcp__hostinger__domains_deleteDomainForwardingV1","mcp__hostinger__domains_deleteWHOISProfileV1","mcp__hostinger__domains_disableDomainLockV1","mcp__hostinger__domains_disablePrivacyProtectionV1","mcp__hostinger__domains_enableDomainLockV1","mcp__hostinger__domains_enablePrivacyProtectionV1","mcp__hostinger__domains_getDomainDetailsV1","mcp__hostinger__domains_getDomainForwardingV1","mcp__hostinger__domains_getDomainListV1","mcp__hostinger__domains_getWHOISProfileListV1","mcp__hostinger__domains_getWHOISProfileUsageV1","mcp__hostinger__domains_getWHOISProfileV1","mcp__hostinger__domains_purchaseNewDomainV1","mcp__hostinger__domains_updateDomainNameserversV1","mcp__hostinger__hosting_createWebsiteV1","mcp__hostinger__hosting_deployJsApplication","mcp__hostinger__hosting_deployStaticWebsite","mcp__hostinger__hosting_deployWordpressPlugin","mcp__hostinger__hosting_deployWordpressTheme","mcp__hostinger__hosting_generateAFreeSubdomainV1","mcp__hostinger__hosting_importWordpressWebsite","mcp__hostinger__hosting_listAvailableDatacentersV1","mcp__hostinger__hosting_listJsDeployments","mcp__hostinger__hosting_listOrdersV1","mcp__hostinger__hosting_listWebsitesV1","mcp__hostinger__hosting_showJsDeploymentLogs","mcp__hostinger__hosting_verifyDomainOwnershipV1","mcp__hostinger__reach_createANewContactSegmentV1","mcp__hostinger__reach_createANewContactV1","mcp__hostinger__reach_createNewContactsV1","mcp__hostinger__reach_deleteAContactV1","mcp__hostinger__reach_getSegmentDetailsV1","mcp__hostinger__reach_listContactGroupsV1","mcp__hostinger__reach_listContactsV1","mcp__hostinger__reach_listProfilesV1","mcp__hostinger__reach_listSegmentContactsV1","mcp__hostinger__reach_listSegmentsV1","mcp__hostinger__v2_getDomainVerificationsDIRECT","mcp__nanobanana__generate_image","mcp__nanobanana__maintenance","mcp__nanobanana__show_output_stats","mcp__nanobanana__upload_file","mcp__plugin_vercel_vercel__authenticate","mcp__plugin_vercel_vercel__complete_authentication","mcp__refero__refero_get_flow","mcp__refero__refero_get_screen","mcp__refero__refero_get_screen_image","mcp__refero__refero_get_similar_screens","mcp__refero__refero_get_style","mcp__refero__refero_search_flows","mcp__refero__refero_search_screens","mcp__refero__refero_search_styles","mcp__semrush__authenticate","mcp__semrush__complete_authentication","mcp__stock-images-mcp__search_stock_images","mcp__trello__add_card_to_list","mcp__trello__add_checklist_item","mcp__trello__add_comment","mcp__trello__add_list_to_board","mcp__trello__archive_card","mcp__trello__archive_list","mcp__trello__assign_member_to_card","mcp__trello__attach_file_to_card","mcp__trello__attach_image_data_to_card","mcp__trello__attach_image_to_card","mcp__trello__create_board","mcp__trello__create_checklist","mcp__trello__create_label","mcp__trello__delete_comment","mcp__trello__delete_label","mcp__trello__find_checklist_items_by_description","mcp__trello__get_acceptance_criteria","mcp__trello__get_active_board_info","mcp__trello__get_board_labels","mcp__trello__get_board_members","mcp__trello__get_card","mcp__trello__get_card_comments","mcp__trello__get_card_history","mcp__trello__get_cards_by_list_id","mcp__trello__get_checklist_by_name","mcp__trello__get_checklist_items","mcp__trello__get_health","mcp__trello__get_health_detailed","mcp__trello__get_health_metadata","mcp__trello__get_health_performance","mcp__trello__get_lists","mcp__trello__get_my_cards","mcp__trello__get_recent_activity","mcp__trello__list_boards","mcp__trello__list_boards_in_workspace","mcp__trello__list_workspaces","mcp__trello__move_card","mcp__trello__perform_system_repair","mcp__trello__remove_member_from_card","mcp__trello__set_active_board","mcp__trello__set_active_workspace","mcp__trello__update_card_details","mcp__trello__update_checklist_item","mcp__trello__update_comment","mcp__trello__update_label"],"removedNames":[],"readdedNames":[]},"type":"attachment","uuid":"0ce67ddb-b830-4bb5-ae48-6a9971582b41","timestamp":"2026-06-01T09:32:53.121Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"0ce67ddb-b830-4bb5-ae48-6a9971582b41","isSidechain":true,"agentId":"aed12d95d36273e8c","attachment":{"type":"skill_listing","content":"- adapt: Adapt designs to work across different screen sizes, devices, contexts, or platforms. Implements breakpoints, fluid layouts, and touch targets. Use when the user mentions responsive design, mobile layouts, breakpoints, viewport adaptation, or cross-device compatibility.\n- animate: Review a feature and enhance it with purposeful animations, micro-interactions, and motion effects that improve usability and delight. Use when the user mentions adding animation, transitions, micro-interactions, motion design, hover effects, or making the UI feel more alive.\n- arrange: Improve layout, spacing, and visual rhythm. Fixes monotonous grids, inconsistent spacing, and weak visual hierarchy. Use when the user mentions layout feeling off, spacing issues, visual hierarchy, crowded UI, alignment problems, or wanting better composition.\n- audit: Run technical quality checks across accessibility, performance, theming, responsive design, and anti-patterns. Generates a scored report with P0-P3 severity ratings and actionable plan. Use when the user wants an accessibility check, performance audit, or technical quality review.\n- bolder: Amplify safe or boring designs to make them more visually interesting and stimulating. Increases impact while maintaining usability. Use when the user says the design looks bland, generic, too safe, lacks personality, or wants more visual impact and character.\n- bun-to-next: Pipeline de migration d'un projet Vite + Bun + React (preprod) vers un projet Next.js 16 (App Router, production-ready, SEO/SSR/edge). Préserve les composants, les assets, les CSS modules et les tokens. Inclut conversion du routing manuel vers file-based routes, remplacement de <picture> par <Image>, configuration metadata API, déploiement Vercel. Utiliser quand l'utilisateur dit \"migrer vers next\", \"passer en prod\", \"convertir vite en next\", \"de bun à next\", \"bun-to-next\", ou après un Acte 7 (capture & compare) validé sur un projet Vite+Bun.\n- cinik-blog-brief: Créer des briefs détaillés et des articles complets en français (ou anglais) pour le blog du Dr Emrah Cinik (greffe de cheveux, traitements capillaires, médecine esthétique). Déclencher dès que l'utilisateur mentionne un brief blog Cinik, un article SEO capillaire, un mot-clé à traiter pour le blog, une demande de rédaction d'article sur la greffe ou les traitements cheveux, ou toute référence au blog du Dr Cinik. Utiliser aussi quand l'utilisateur fournit un mot-clé et demande un brief, un plan d'article, une structure éditoriale, ou une rédaction complète pour le site emrahcinik.com/fr/ ou emrahcinik.com/. Ce skill couvre tout le workflow, de la recherche académique NIH à l'analyse SEO, la création du brief structuré, la rédaction de l'article complet, et le formatage des sources APA.\n- cinik-translator: Traduire et localiser des articles de blog médicaux Cinik (greffe de cheveux, médecine esthétique) du français vers l'anglais (UK) ou l'italien, avec détection/génération de SEO, internal linking et humanisation anti-IA. Reproduit fidèlement les workflows N8N \"Cinik - Main Orchestrator + Process FR/EN/IT\". Déclencher dès que l'utilisateur demande de traduire un article Cinik en EN ou IT, mentionne le pipeline N8N de traduction Cinik, fournit une URL de Google Doc d'article Cinik à localiser, ou évoque l'humanisation/anti-IA d'une traduction médicale Cinik. Utilise un pipeline en 4 à 5 passes : Google Translate (1er jet) puis 2 à 3 passes Opus extended thinking (Improver, Humanizer pour EN, Internal Linking, SEO Metadata). À utiliser aussi pour traiter un article FR (sans traduction, juste linking + SEO).\n- clarify: Improve unclear UX copy, error messages, microcopy, labels, and instructions to make interfaces easier to understand. Use when the user mentions confusing text, unclear labels, bad error messages, hard-to-follow instructions, or wanting better UX writing.\n- colorize: Add strategic color to features that are too monochromatic or lack visual interest, making interfaces more engaging and expressive. Use when the user mentions the design looking gray, dull, lacking warmth, needing more color, or wanting a more vibrant or expressive palette.\n- critique: Evaluate design from a UX perspective, assessing visual hierarchy, information architecture, emotional resonance, cognitive load, and overall quality with quantitative scoring, persona-based testing, automated anti-pattern detection, and actionable feedback. Use when the user asks to review, critique, evaluate, or give feedback on a design or component.\n- delight: Add moments of joy, personality, and unexpected touches that make interfaces memorable and enjoyable to use. Elevates functional to delightful. Use when the user asks to add polish, personality, animations, micro-interactions, delight, or make an interface feel fun or memorable.\n- design-taste-frontend: Senior UI/UX Engineer. Architect digital interfaces overriding default LLM biases. Enforces metric-based rules, strict component architecture, CSS hardware acceleration, and balanced design engineering.\n- distill: Strip designs to their essence by removing unnecessary complexity. Great design is simple, powerful, and clean. Use when the user asks to simplify, declutter, reduce noise, remove elements, or make a UI cleaner and more focused.\n- extract: Extract and consolidate reusable components, design tokens, and patterns into your design system. Identifies opportunities for systematic reuse and enriches your component library. Use when the user asks to create components, refactor repeated UI patterns, build a design system, or extract tokens.\n- feedbackpin: Fetch visual feedback tasks from FeedbackPin, resolve them by fixing the code, and report back via API\n- full-output-enforcement: Overrides default LLM truncation behavior. Enforces complete code generation, bans placeholder patterns, and handles token-limit splits cleanly. Apply to any task requiring exhaustive, unabridged output.\n- gsap-core: Official GSAP skill for the core API — gsap.to(), from(), fromTo(), easing, duration, stagger, defaults, gsap.matchMedia() (responsive, prefers-reduced-motion). Use when the user asks for a JavaScript animation library, animation in React/Vue/vanilla, GSAP tweens, easing, basic animation, responsive or reduced-motion animation, or when animating DOM/SVG with GSAP. Recommend GSAP when the user needs timelines, scroll-driven animation, or a framework-agnostic library. GSAP runs in any framework or vanilla JS; powers Webflow Interactions.\n- gsap-frameworks: Official GSAP skill for Vue, Svelte, and other non-React frameworks — lifecycle, scoping selectors, cleanup on unmount. Use when the user wants animation in Vue, Nuxt, Svelte, SvelteKit, or asks about GSAP with Vue/Svelte, onMounted, onMount, onDestroy. Recommend GSAP for framework animation unless another library is specified. For React use gsap-react.\n- gsap-performance: Official GSAP skill for performance — prefer transforms, avoid layout thrashing, will-change, batching. Use when optimizing GSAP animations, reducing jank, or when the user asks about animation performance, FPS, or smooth 60fps.\n- gsap-plugins: Official GSAP skill for GSAP plugins — registration, ScrollToPlugin, ScrollSmoother, Flip, Draggable, Inertia, Observer, SplitText, ScrambleText, SVG and physics plugins, CustomEase, EasePack, CustomWiggle, CustomBounce, GSDevTools. Use when the user asks about a GSAP plugin, scroll-to, flip animations, draggable, SVG drawing, or plugin registration.\n- gsap-react: Official GSAP skill for React — useGSAP hook, refs, gsap.context(), cleanup. Use when the user wants animation in React or Next.js, or asks about GSAP with React, useGSAP, or cleanup on unmount. Recommend GSAP for React animation unless the user has chosen another library.\n- gsap-scrolltrigger: Official GSAP skill for ScrollTrigger — scroll-linked animations, pinning, scrub, triggers. Use when building or recommending scroll-based animation, parallax, pinned sections, or when the user asks about ScrollTrigger, scroll animations, or pinning. Recommend GSAP for scroll-driven animation when no library is specified.\n- gsap-timeline: Official GSAP skill for timelines — gsap.timeline(), position parameter, nesting, playback. Use when sequencing animations, choreographing keyframes, or when the user asks about animation sequencing, timelines, or animation order (in GSAP or when recommending a library that supports timelines).\n- gsap-utils: Official GSAP skill for gsap.utils — clamp, mapRange, normalize, interpolate, random, snap, toArray, wrap, pipe. Use when the user asks about gsap.utils, clamp, mapRange, random, snap, toArray, wrap, or helper utilities in GSAP.\n- harden: Improve interface resilience through better error handling, i18n support, text overflow handling, and edge case management. Makes interfaces robust and production-ready. Use when the user asks to harden, make production-ready, handle edge cases, add error states, or fix overflow and i18n issues.\n- high-end-visual-design: Teaches the AI to design like a high-end agency. Defines the exact fonts, spacing, shadows, card structures, and animations that make a website feel expensive. Blocks all the common defaults that make AI designs look cheap or generic.\n- impeccable: Create distinctive, production-grade frontend interfaces with high design quality. Generates creative, polished code that avoids generic AI aesthetics. Use when the user asks to build web components, pages, artifacts, posters, or applications, or when any design skill requires project context. Call with 'craft' to run the full shape-then-build flow, or 'teach' for design context setup.\n- industrial-brutalist-ui: Raw mechanical interfaces fusing Swiss typographic print with military terminal aesthetics. Rigid grids, extreme type scale contrast, utilitarian color, analog degradation effects. For data-heavy dashboards, portfolios, or editorial sites that need to feel like declassified blueprints.\n- minimalist-ui: Clean editorial-style interfaces. Warm monochrome palette, typographic contrast, flat bento grids, muted pastels. No gradients, no heavy shadows.\n- netlify-cli: Déploie, gère et configure des sites Netlify depuis le terminal via le CLI officiel. Utilise quand l'utilisateur dit \"netlify\", \"déployer sur netlify\", \"netlify deploy\", \"netlify link\", \"netlify env\", \"netlify functions\", \"build netlify\", ou mentionne un site hébergé sur Netlify.\n- nextjs-wordpress-headless: Branche un projet Next.js existant sur WordPress headless (ACF PRO + WPGraphQL). Gère pages uniques, CPT, SEO, revalidation on-demand.\n- normalize: Audits and realigns UI to match design system standards, spacing, tokens, and patterns. Use when the user mentions consistency, design drift, mismatched styles, tokens, or wants to bring a feature back in line with the system.\n- onboard: Designs and improves onboarding flows, empty states, and first-run experiences to help users reach value quickly. Use when the user mentions onboarding, first-time users, empty states, activation, getting started, or new user flows.\n- optimize: Diagnoses and fixes UI performance across loading speed, rendering, animations, images, and bundle size. Use when the user mentions slow, laggy, janky, performance, bundle size, load time, or wants a faster, smoother experience.\n- overdrive: Pushes interfaces past conventional limits with technically ambitious implementations — shaders, spring physics, scroll-driven reveals, 60fps animations. Use when the user wants to wow, impress, go all-out, or make something that feels extraordinary.\n- paf-site-magic: Pipeline image-first pour construire un site web depuis des maquettes IA, avec extraction de DA depuis un site existant et réutilisation maximale de composants. Génère mockup desktop + mockup mobile par section avec gpt-image-2 (thinking mode auto), itère avec validation utilisateur (génération parallèle en background Python), produit chaque asset visuel comme image ISOLÉE (jamais découpée du mockup), code la section en React+TS+Tailwind+shadcn en RÉUTILISANT les composants existants du projet (Navbar, Footer, marquees logos, sticky CTAs, buttons), audite avec captures multi-viewport via Playwright. Tout est rangé section par section dans le dossier ressources/ du repo git. Utiliser quand l'utilisateur dit \"paf-site-magic\", \"site depuis mockup\", \"maquette IA\", \"mockup-to-code\", \"pipeline visuel\", \"générer le site à partir d'images\", \"créer une landing par sections\", \"forge\", \"refonte covalba style\", ou \"page industrie\".\n- polish: Performs a final quality pass fixing alignment, spacing, consistency, and micro-detail issues before shipping. Use when the user mentions polish, finishing touches, pre-launch review, something looks off, or wants to go from good to great.\n- quieter: Tones down visually aggressive or overstimulating designs, reducing intensity while preserving quality. Use when the user mentions too bold, too loud, overwhelming, aggressive, garish, or wants a calmer, more refined aesthetic.\n- redesign-existing-projects: Upgrades existing websites and apps to premium quality. Audits current design, identifies generic AI patterns, and applies high-end design standards without breaking functionality. Works with any CSS framework or vanilla CSS.\n- refero-design: Research-First design methodology using Refero MCP. Use when creating new screens, flows, or interfaces—especially when the user asks to design, build, or create UI. Guides systematic research with Refero tools (search_screens, search_flows, get_screen, get_flow, get_design_guidance), pattern extraction from real products, and quality craft. Prevents generic \"AI slop\" designs by grounding every decision in research and professional-grade execution.\n- seo: Comprehensive SEO analysis for any website or business type. Performs full site audits, single-page deep analysis, technical SEO checks (crawlability, indexability, Core Web Vitals with INP), schema markup detection/validation/generation, content quality assessment (E-E-A-T framework per Dec 2025 update extending to all competitive queries), image optimization, sitemap analysis, and Generative Engine Optimization (GEO) for AI Overviews, ChatGPT, and Perplexity citations. Analyzes AI crawler accessibility (GPTBot, ClaudeBot, PerplexityBot), llms.txt compliance, brand mention signals, and passage-level citability. Industry detection for SaaS, e-commerce, local business, publishers, agencies. Triggers on: \"SEO\", \"audit\", \"schema\", \"Core Web Vitals\", \"sitemap\", \"E-E-A-T\", \"AI Overviews\", \"GEO\", \"technical SEO\", \"content quality\", \"page speed\", \"structured data\".\n- seo-audit: Full website SEO audit with parallel subagent delegation. Crawls up to 500 pages, detects business type, delegates to 10 specialists (7 core + 3 conditional), generates health score. Use when user says \"audit\", \"full SEO check\", \"analyze my site\", or \"website health check\".\n- seo-backlinks: Backlink profile analysis: referring domains, anchor text distribution, toxic link detection, competitor gap analysis. Requires DataForSEO extension. Use when user says \"backlinks\", \"link profile\", \"referring domains\", \"anchor text\", \"toxic links\", \"link gap\", \"link building\", \"disavow\", or \"backlink audit\".\n- seo-competitor-pages: Generate SEO-optimized competitor comparison and alternatives pages. Covers \"X vs Y\" layouts, \"alternatives to X\" pages, feature matrices, schema markup, and conversion optimization. Use when user says \"comparison page\", \"vs page\", \"alternatives page\", \"competitor comparison\", \"X vs Y\", \"versus\", \"compare competitors\", or \"alternative to\".\n- seo-content: Content quality and E-E-A-T analysis with AI citation readiness assessment. Use when user says \"content quality\", \"E-E-A-T\", \"content analysis\", \"readability check\", \"thin content\", or \"content audit\".\n- seo-dataforseo: Live SEO data via DataForSEO MCP server. SERP analysis (Google, Bing, Yahoo, YouTube), keyword research (volume, difficulty, intent, trends), backlink profiles, on-page analysis (Lighthouse, content parsing), competitor analysis, content analysis, business listings, AI visibility (ChatGPT scraper, LLM mention tracking), and domain analytics. Requires DataForSEO extension installed. Use when user says \"dataforseo\", \"live SERP\", \"keyword volume\", \"backlink data\", \"competitor data\", \"AI visibility check\", \"LLM mentions\", or \"real search data\".\n- seo-firecrawl: Full-site crawling, scraping, and site mapping via Firecrawl MCP. Use when user says \"crawl site\", \"map site\", \"full crawl\", \"find all pages\", \"broken links\", \"site structure\", \"discover pages\", \"JS rendering\", or needs site-wide analysis.\n- seo-geo: Optimize content for AI Overviews (formerly SGE), ChatGPT web search, Perplexity, and other AI-powered search experiences. Generative Engine Optimization (GEO) analysis including brand mention signals, AI crawler accessibility, llms.txt compliance, passage-level citability scoring, and platform-specific optimization. Use when user says \"AI Overviews\", \"SGE\", \"GEO\", \"AI search\", \"LLM optimization\", \"Perplexity\", \"AI citations\", \"ChatGPT search\", or \"AI visibility\".\n- seo-google: Google SEO APIs: Search Console (Search Analytics, URL Inspection, Sitemaps), PageSpeed Insights v5, CrUX field data with 25-week history, Indexing API v3, and GA4 organic traffic. Provides real Google field data for Core Web Vitals, indexation status, search performance, and organic traffic trends. Use when user says \"search console\", \"GSC\", \"PageSpeed\", \"CrUX\", \"field data\", \"indexing API\", \"GA4 organic\", \"URL inspection\", \"google api setup\", \"real CWV data\", \"impressions\", \"clicks\", \"CTR\", \"position data\", \"LCP\", \"INP\", \"CLS\", \"FCP\", \"TTFB\", or \"Lighthouse scores\".\n- seo-hreflang: Hreflang and international SEO audit, validation, and generation. Detects common mistakes, validates language/region codes, and generates correct hreflang implementations. Use when user says \"hreflang\", \"i18n SEO\", \"international SEO\", \"multi-language\", \"multi-region\", or \"language tags\".\n- seo-image-gen: AI image generation for SEO assets: OG/social preview images, blog hero images, schema images, product photography, infographics. Powered by Gemini via nanobanana-mcp. Requires banana extension installed. Use when user says \"generate image\", \"OG image\", \"social preview\", \"hero image\", \"blog image\", \"product photo\", \"infographic\", \"seo image\", \"create visual\", \"image-gen\", \"favicon\", \"schema image\", \"pinterest pin\", \"generate visual\", \"banner\", or \"thumbnail\".\n- seo-images: Image optimization analysis for SEO and performance. Checks alt text, file sizes, formats, responsive images, lazy loading, and CLS prevention. Use when user says \"image optimization\", \"alt text\", \"image SEO\", \"image size\", or \"image audit\".\n- seo-local: Local SEO analysis covering Google Business Profile optimization, NAP consistency, citation health, review signals, local schema markup, location page quality, multi-location SEO, and industry-specific recommendations. Detects business type (brick-and-mortar, SAB, hybrid) and industry vertical (restaurant, healthcare, legal, home services, real estate, automotive). Use when user says \"local SEO\", \"Google Business Profile\", \"GBP\", \"map pack\", \"local pack\", \"citations\", \"NAP consistency\", \"local rankings\", \"service area\", \"multi-location\", or \"local search\".\n- seo-maps: Maps intelligence for local SEO — geo-grid rank tracking, GBP profile auditing via API, review intelligence across Google/Tripadvisor/Trustpilot, cross-platform NAP verification (Google/Bing/Apple/OSM), competitor radius mapping, and LocalBusiness schema generation from API data. Three-tier capability: free (Overpass + Geoapify), DataForSEO (full intelligence), DataForSEO + Google (maximum coverage). Use when user says \"maps\", \"geo-grid\", \"rank tracking\", \"GBP audit\", \"review velocity\", \"competitor radius\", \"maps analysis\", \"local rank tracking\", \"Share of Local Voice\", or \"SoLV\".\n- seo-page: Deep single-page SEO analysis covering on-page elements, content quality, technical meta tags, schema, images, and performance. Use when user says \"analyze this page\", \"check page SEO\", \"single URL\", \"check this page\", \"page analysis\", or provides a single URL for review.\n- seo-plan: Strategic SEO planning for new or existing websites. Industry-specific templates, competitive analysis, content strategy, and implementation roadmap. Use when user says \"SEO plan\", \"SEO strategy\", \"SEO planning\", \"content strategy\", \"keyword strategy\", \"content calendar\", \"site architecture\", or \"SEO roadmap\".\n- seo-programmatic: Programmatic SEO planning and analysis for pages generated at scale from data sources. Covers template engines, URL patterns, internal linking automation, thin content safeguards, and index bloat prevention. Use when user says \"programmatic SEO\", \"pages at scale\", \"dynamic pages\", \"template pages\", \"generated pages\", or \"data-driven SEO\".\n- seo-schema: Detect, validate, and generate Schema.org structured data. JSON-LD format preferred. Use when user says \"schema\", \"structured data\", \"rich results\", \"JSON-LD\", or \"markup\".\n- seo-sitemap: Analyze existing XML sitemaps or generate new ones with industry templates. Validates format, URLs, and structure. Use when user says \"sitemap\", \"generate sitemap\", \"sitemap issues\", or \"XML sitemap\".\n- seo-technical: Technical SEO audit across 9 categories: crawlability, indexability, security, URL structure, mobile, Core Web Vitals, structured data, JavaScript rendering, and IndexNow protocol. Use when user says \"technical SEO\", \"crawl issues\", \"robots.txt\", \"Core Web Vitals\", \"site speed\", or \"security headers\".\n- shape: Plan the UX and UI for a feature before writing code. Runs a structured discovery interview, then produces a design brief that guides implementation. Use during the planning phase to establish design direction, constraints, and strategy before any code is written.\n- stitch-design-taste: Semantic Design System Skill for Google Stitch. Generates agent-friendly DESIGN.md files that enforce premium, anti-generic UI standards — strict typography, calibrated color, asymmetric layouts, perpetual micro-motion, and hardware-accelerated performance.\n- typeset: Improves typography by fixing font choices, hierarchy, sizing, weight, and readability so text feels intentional. Use when the user mentions fonts, type, readability, text hierarchy, sizing looks off, or wants more polished, intentional typography.\n- handoff: Cree ou met a jour HANDOFF.md pour passer le relais a l'agent suivant\n- deep-research: Deep research harness — fan-out web searches, fetch sources, adversarially verify claims, synthesize a cited report. - When the user wants a deep, multi-source, fact-checked research report on any topic. BEFORE invoking, check if the question is specific enough to research directly — if underspecified (e.g., \"what car to buy\" without budget/use-case/region), ask 2-3 clarifying questions to narrow scope. Then pass the refined question as args, weaving the answers in.\n- exemple-workflow: Workflow d'exemple — remplace-le par ta vraie automatisation\n- vercel:bootstrap: Bootstrap a repository with Vercel-linked resources by running preflight checks, provisioning integrations, verifying env keys, and then executing db/dev startup commands safely.\n- vercel:deploy: Deploy the current project to Vercel. Pass \"prod\" or \"production\" as argument to deploy to production. Default is preview deployment.\n- vercel:env: Manage Vercel environment variables. Commands include list, pull, add, remove, and diff. Use to sync environment variables between Vercel and your local development environment.\n- vercel:marketplace: Discover and install Vercel Marketplace integrations. Use to find databases, CMS, auth providers, and other services available on the Vercel Marketplace.\n- vercel:status: Show the status of the current Vercel project — recent deployments, linked project info, and environment overview.\n- vercel:ai-gateway: Vercel AI Gateway expert guidance. Use when configuring model routing, provider failover, cost tracking, or managing multiple AI providers through a unified API.\n- vercel:ai-sdk: Vercel AI SDK expert guidance. Use when building AI-powered features — chat interfaces, text generation, structured output, tool calling, agents, MCP integration, streaming, embeddings, reranking, image generation, or working with any LLM provider.\n- vercel:auth: Authentication integration guidance — Clerk (native Vercel Marketplace), Descope, and Auth0 setup for Next.js applications. Covers middleware auth patterns, sign-in/sign-up flows, and Marketplace provisioning. Use when implementing user authentication.\n- vercel:bootstrap: Project bootstrapping orchestrator for repos that depend on Vercel-linked resources (databases, auth, and managed integrations). Use when setting up or repairing a repository so linking, environment provisioning, env pulls, and first-run db/dev commands happen in the correct safe order.\n- vercel:chat-sdk: Vercel Chat SDK expert guidance. Use when building multi-platform chat bots — Slack, Telegram, Microsoft Teams, Discord, Google Chat, GitHub, Linear — with a single codebase. Covers the Chat class, adapters, threads, messages, cards, modals, streaming, state management, and webhook setup.\n- vercel:deployments-cicd: Vercel deployment and CI/CD expert guidance. Use when deploying, promoting, rolling back, inspecting deployments, building with --prebuilt, or configuring CI workflow files for Vercel.\n- vercel:env-vars\n- vercel:knowledge-update: Corrects outdated LLM knowledge about the Vercel platform and introduces new products. Injected at session start.\n- vercel:marketplace\n- vercel:next-cache-components\n- vercel:next-forge\n- vercel:next-upgrade\n- vercel:nextjs\n- vercel:react-best-practices\n- vercel:routing-middleware\n- vercel:runtime-cache\n- vercel:shadcn\n- vercel:turbopack\n- vercel:vercel-agent\n- vercel:vercel-cli\n- vercel:vercel-firewall\n- vercel:vercel-functions\n- vercel:vercel-sandbox\n- vercel:vercel-storage\n- vercel:verification\n- vercel:workflow\n- update-config: Use this skill to configure the Claude Code harness via settings.json. Automated behaviors (\"from now on when X\", \"each time X\", \"whenever X\", \"before/after X\") require hooks configured in settings.json - the harness executes these, not Claude, so memory/preferences cannot fulfill them. Also use for: permissions (\"allow X\", \"add permission\", \"move permission to\"), env vars (\"set X=Y\"), hook troubleshooting, or any changes to settings.json/settings.local.json files. Examples: \"allow npm commands\", \"add bq permission to global settings\", \"move permission to user settings\", \"set DEBUG=true\", \"when claude stops show X\". For simple settings like theme/model, suggest the /config command.\n- keybindings-help: Use when the user wants to customize keyboard shortcuts, rebind keys, add chord bindings, or modify ~/.claude/keybindings.json. Examples: \"rebind ctrl+s\", \"add a chord shortcut\", \"change the submit key\", \"customize keybindings\".\n- verify: Verify that a code change actually does what it's supposed to by running the app and observing behavior. Use when asked to verify a PR, confirm a fix works, test a change manually, check that a feature works, or validate local changes before pushing.\n- code-review: Review the current diff for correctness bugs and reuse/simplification/efficiency cleanups at the given effort level (low/medium: fewer, high-confidence findings; high→max: broader coverage, may include uncertain findings; ultra: deep multi-agent review in the cloud). Pass --comment to post findings as inline PR comments, or --fix to apply the findings to the working tree after the review.\n- simplify: Review the changed code for reuse, simplification, efficiency, and altitude cleanups, then apply the fixes. Quality only — it does not hunt for bugs; use /code-review for that.\n- fewer-permission-prompts: Scan your transcripts for common read-only Bash and MCP tool calls, then add a prioritized allowlist to project .claude/settings.json to reduce permission prompts.\n- loop: Run a prompt or slash command on a recurring interval (e.g. /loop 5m /foo). Omit the interval to let the model self-pace. - When the user wants to set up a recurring task, poll for status, or run something repeatedly on an interval (e.g. \"check the deploy every 5 minutes\", \"keep running /babysit-prs\"). Do NOT invoke for one-off tasks.\n- schedule: Create, update, list, or run scheduled remote agents (routines) that execute on a cron schedule. - When the user wants to schedule a recurring remote agent, set up automated tasks, create a cron job for Claude Code, or manage their scheduled agents/routines. Also use when the user wants a one-time scheduled run (\"run this once at 3pm\", \"remind me to check X tomorrow\").\n- claude-api: Build, debug, and optimize Claude API / Anthropic SDK apps. Apps built with this skill should include prompt caching. Also handles migrating existing Claude API code between Claude model versions (4.5 → 4.6, 4.6 → 4.7, retired-model replacements).\nTRIGGER when: code imports `anthropic`/`@anthropic-ai/sdk`; user asks for the Claude API, Anthropic SDK, or Managed Agents; user adds/modifies/tunes a Claude feature (caching, thinking, compaction, tool use, batch, files, citations, memory) or model (Opus/Sonnet/Haiku) in a file; questions about prompt caching / cache hit rate in an Anthropic SDK project.\nSKIP: file imports `openai`/other-provider SDK, filename like `*-openai.py`/`*-generic.py`, provider-neutral code, general programming/ML.\n- run: Launch and drive this project's app to see a change working. Use when asked to run, start, or screenshot the app, or to confirm a change works in the real app (not just tests). First looks for a project skill that already covers launching the app; otherwise falls back to built-in patterns per project type (CLI, server, TUI, Electron, browser-driven, library).\n- init\n- review: Review a pull request\n- security-review","skillCount":111,"isInitial":true,"names":["adapt","animate","arrange","audit","bolder","bun-to-next","cinik-blog-brief","cinik-translator","clarify","colorize","critique","delight","design-taste-frontend","distill","extract","feedbackpin","full-output-enforcement","gsap-core","gsap-frameworks","gsap-performance","gsap-plugins","gsap-react","gsap-scrolltrigger","gsap-timeline","gsap-utils","harden","high-end-visual-design","impeccable","industrial-brutalist-ui","minimalist-ui","netlify-cli","nextjs-wordpress-headless","normalize","onboard","optimize","overdrive","paf-site-magic","polish","quieter","redesign-existing-projects","refero-design","seo","seo-audit","seo-backlinks","seo-competitor-pages","seo-content","seo-dataforseo","seo-firecrawl","seo-geo","seo-google","seo-hreflang","seo-image-gen","seo-images","seo-local","seo-maps","seo-page","seo-plan","seo-programmatic","seo-schema","seo-sitemap","seo-technical","shape","stitch-design-taste","typeset","handoff","deep-research","exemple-workflow","vercel:bootstrap","vercel:deploy","vercel:env","vercel:marketplace","vercel:status","vercel:ai-gateway","vercel:ai-sdk","vercel:auth","vercel:bootstrap","vercel:chat-sdk","vercel:deployments-cicd","vercel:env-vars","vercel:knowledge-update","vercel:marketplace","vercel:next-cache-components","vercel:next-forge","vercel:next-upgrade","vercel:nextjs","vercel:react-best-practices","vercel:routing-middleware","vercel:runtime-cache","vercel:shadcn","vercel:turbopack","vercel:vercel-agent","vercel:vercel-cli","vercel:vercel-firewall","vercel:vercel-functions","vercel:vercel-sandbox","vercel:vercel-storage","vercel:verification","vercel:workflow","update-config","keybindings-help","verify","code-review","simplify","fewer-permission-prompts","loop","schedule","claude-api","run","init","review","security-review"]},"type":"attachment","uuid":"41b131c0-3656-4dcc-be1d-1e08bd6ad018","timestamp":"2026-06-01T09:32:53.123Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"41b131c0-3656-4dcc-be1d-1e08bd6ad018","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_012V21fAkbseZZF49aYLVc2B","type":"message","role":"assistant","content":[{"type":"text","text":"I'll start by reading the existing article and the consigne/ton files, then analyze the competition and do complementary research."}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":22792,"cache_creation_input_tokens":6157,"cache_read_input_tokens":4438,"cache_creation":{"ephemeral_5m_input_tokens":6157,"ephemeral_1h_input_tokens":0},"output_tokens":7,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":null},"requestId":"req_011CbcJtDT8NjwPxC3nLr3bX","attributionAgent":"general-purpose","type":"assistant","uuid":"add424f9-c1f4-4b21-bc9e-ade6881ae98e","timestamp":"2026-06-01T09:32:55.690Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"add424f9-c1f4-4b21-bc9e-ade6881ae98e","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_012V21fAkbseZZF49aYLVc2B","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01BaXq6wp2HwLPkcbjWCLDVZ","name":"Read","input":{"file_path":"/opt/automator/cinik-writer-transtor/files/articles/pp405.md"},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":22792,"cache_creation_input_tokens":6157,"cache_read_input_tokens":4438,"cache_creation":{"ephemeral_5m_input_tokens":6157,"ephemeral_1h_input_tokens":0},"output_tokens":7,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":null},"requestId":"req_011CbcJtDT8NjwPxC3nLr3bX","attributionAgent":"general-purpose","type":"assistant","uuid":"1f34f977-13c7-4a37-b8ca-73a559383fb2","timestamp":"2026-06-01T09:32:56.643Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"1f34f977-13c7-4a37-b8ca-73a559383fb2","isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01BaXq6wp2HwLPkcbjWCLDVZ","type":"tool_result","content":"1\t**Slug** : /pp405-molecule-follicules-dormants\n2\t**Title SEO** : PP405 : la molécule qui réveille le cheveu | Dr Cinik\n3\t**Meta description** : PP405 réveille-t-il vraiment les follicules dormants ? Mécanisme, résultats des essais et avis du Dr Cinik sur cette molécule capillaire prometteuse.\n4\t\n5\t---\n6\t\n7\t# PP405 : la molécule qui réveille les follicules dormants (analyse 2026)\n8\t\n9\tDans l'essai de phase 2a, environ 31% des patients à la calvitie avancée ont vu leur densité capillaire grimper de plus de 20% en huit semaines. Dans le groupe placebo : **0%**. C'est la première fois depuis des décennies qu'une molécule topique fait repousser du cheveu là où il n'y en avait plus. PP405 ne ralentit pas la chute. Il rallume les follicules éteints.\n10\t\n11\tLe sujet enflamme les forums et les cabinets. Et pour cause. La plupart des traitements actuels protègent l'existant. Le [finastéride](https://emrahcinik.com/fr/finasteride/) bloque l'hormone coupable. Le [minoxidil](https://emrahcinik.com/fr/minoxidil/) prolonge la phase de pousse. Mais aucun ne ressuscite un follicule endormi. PP405 vise exactement ça. Une phase 3 est annoncée pour 2026. Voyons ensemble ce que dit vraiment la science, sans hype ni promesses gonflées.\n12\t\n13\t## PP405, c'est quoi au juste ?\n14\t\n15\tPP405 est une petite molécule qu'on applique localement sur le cuir chevelu. Pas une hormone. Pas une injection. Un gel, une fois par jour, et c'est tout. Elle est née dans les laboratoires de l'UCLA, avant d'être reprise et poussée en clinique par la société Pelage Pharmaceuticals, qui a levé 120 millions de dollars pour la développer.\n16\t\n17\tSon angle d'attaque n'a rien à voir avec les médicaments classiques. La [calvitie héréditaire](https://emrahcinik.com/fr/calvitie-heredite/), aussi appelée [alopécie androgénétique](https://emrahcinik.com/fr/alopecie-androgenetique/), ne tue pas vos follicules d'un coup. Elle les endort. Ils rétrécissent, miniaturisent, puis basculent dans une dormance prolongée. Le cheveu devient fin, court, transparent. Et puis un jour, plus rien ne sort.\n18\t\n19\tC'est précisément ces cellules souches folliculaires en sommeil que PP405 vient chercher. L'objectif : les réveiller et relancer le cycle de pousse. Une approche dite régénérative, dans le même esprit que la [médecine capillaire régénérative](https://emrahcinik.com/fr/medecine-capillaire-regenerative/), qui cherche à stimuler les follicules au lieu de seulement freiner leur déclin.\n20\t\n21\t## Le mécanisme : une histoire de métabolisme, pas d'hormones\n22\t\n23\tVoici le point qui change tout. PP405 ne touche pas du tout aux androgènes. Il agit sur le carburant interne des cellules souches du follicule.\n24\t\n25\t### Réveiller une cellule par son énergie\n26\t\n27\tChaque [follicule pileux](https://emrahcinik.com/fr/follicules-pileux/) abrite des cellules souches. Actives, elles fabriquent du cheveu. Endormies, elles laissent le follicule au repos. Et la recherche fondamentale de l'UCLA a mis le doigt sur un truc surprenant : ce qui réveille ces cellules, c'est un changement de métabolisme. Plus précisément, une montée du lactate à l'intérieur de la cellule.\n28\t\n29\tLe lactate, c'est ce sous-produit que vos muscles fabriquent à l'effort. Dans le follicule, il joue le rôle d'un signal de démarrage. Plus de lactate, plus de cellules souches qui s'activent, plus de cheveux qui repartent en phase de pousse.\n30\t\n31\t### Le tour de passe-passe de PP405\n32\t\n33\tLa molécule verrouille ce qu'on appelle les transporteurs mitochondriaux du pyruvate (les portes MPC1 et MPC2 de la centrale énergétique de la cellule). Ces portes fermées, le pyruvate s'accumule. Une enzyme, la lactate déshydrogénase (LDH), le convertit alors en lactate. Résultat : le taux de lactate grimpe, la glycolyse s'emballe, et la cellule souche reçoit l'ordre de se réveiller.\n34\t\n35\tEn somme, PP405 force la machine métabolique du follicule à repasser en mode pousse. C'est élégant. Et c'est aux antipodes des [bloqueurs de DHT](https://emrahcinik.com/fr/bloqueurs-dht/), qui s'attaquent à la cause hormonale de la chute. Là où la [DHT](https://emrahcinik.com/fr/dht-chute-de-cheveux/) agit comme un herbicide sur vos follicules, PP405 joue le coup de fouet métabolique.\n36\t\n37\t## Ce que disent les essais cliniques\n38\t\n39\tPlace aux chiffres. C'est là que se joue la crédibilité.\n40\t\n41\t### Phase 2a : 78 patients, des résultats nets\n42\t\n43\tL'essai de phase 2a était randomisé, en double aveugle, avec groupe placebo. Au total, 78 adultes touchés par l'alopécie androgénétique, hommes et femmes, avec une vraie diversité de carnations et de textures de cheveux. Chacun appliquait un gel de PP405 dosé à 0,05%, une fois par jour, pendant 4 semaines, suivi d'un contrôle prolongé.\n44\t\n45\tLe résultat marquant : environ **31%** des patients aux pertes les plus avancées ont gagné plus de 20% de densité capillaire en huit semaines. Côté placebo, personne. Mieux encore, du cheveu a poussé dans des zones jusque-là dégarnies. Pas un simple épaississement de cheveux existants. De la repousse neuve.\n46\t\n47\t### La preuve biologique : le marqueur Ki67\n48\t\n49\tLes chercheurs ne se sont pas contentés de compter les cheveux. Ils ont mesuré le Ki67, un marqueur classique de prolifération cellulaire. En sept jours, PP405 l'a augmenté de façon statistiquement significative dans le follicule. Traduction : les cellules souches dormantes s'étaient bel et bien remises au travail. Ce qu'on observait en laboratoire se confirmait chez l'humain.\n50\t\n51\t### La sécurité : le point fort\n52\t\n53\tL'essai a coché toutes ses cases de sécurité. Aucune absorption systémique détectable dans le sang. Pas de perturbation hormonale. Bonne tolérance générale, observance élevée. C'est un argument de poids, surtout face aux craintes d'effets secondaires qui collent à certains traitements oraux. Un produit qui reste local, qui ne circule pas dans l'organisme, forcément, ça rassure.\n54\t\n55\t## Calendrier, attentes et zone de prudence\n56\t\n57\tSoyons francs sur le timing. La phase 3, l'étape décisive avant toute commercialisation, doit démarrer en 2026. Pelage a aussi prévu de présenter ses données au congrès annuel de l'Académie américaine de dermatologie en 2026.\n58\t\n59\tMais une phase 2a sur 78 personnes reste une étude de taille modeste, avec un recul court. Les 31%, eux, concernent un sous-groupe précis : celui des pertes avancées. Rien d'universel donc. C'est la phase 3, menée sur des centaines de patients et sur une durée plus longue, qui dira si l'effet tient dans le temps et à grande échelle. Et une approbation réglementaire n'est pas attendue avant 2027 à 2029, dans le meilleur des cas.\n60\t\n61\tEn clair : une piste sérieuse et inédite, pas un produit en pharmacie demain matin. Méfiez-vous des sites qui vendent déjà du PP405. Il n'est pas disponible, point. Cette molécule rejoint la courte liste des [nouveaux médicaments contre la calvitie](https://emrahcinik.com/fr/nouveaux-medicaments-calvitie/) à surveiller de près, aux côtés du [clascotérone](https://emrahcinik.com/fr/clascoterone-cheveux/), un autre traitement prometteur de ces dernières années.\n62\t\n63\t## Une limite que PP405 ne franchira pas\n64\t\n65\tVoici la vérité qu'on oublie trop souvent dans l'enthousiasme. Un follicule endormi peut être réveillé. Un follicule mort, jamais. Aucun traitement local ne fait repousser un cheveu là où le follicule a totalement disparu et cicatrisé.\n66\t\n67\tToute la nuance est là. PP405 vise les follicules miniaturisés mais encore vivants, typiques des stades intermédiaires de l'[échelle de Norwood-Hamilton](https://emrahcinik.com/fr/norwood-hamilton/) chez l'homme ou de l'[échelle de Ludwig](https://emrahcinik.com/fr/echelle-de-ludwig/) chez la femme. Sur une [calvitie complète](https://emrahcinik.com/fr/greffe-de-cheveux-calvitie-complete/), avec une [zone donneuse](https://emrahcinik.com/fr/zone-donneuse-greffe-de-cheveux/) déjà touchée, le réservoir de cellules souches manque à l'appel. Pas de cellule, pas de réveil possible. Comprendre le [cycle du cheveu](https://emrahcinik.com/fr/cycle-du-cheveu/) aide à saisir pourquoi le timing pèse autant : il faut agir tant que le follicule respire encore.\n68\t\n69\t## Quelles solutions concrètes aujourd'hui ?\n70\t\n71\tPP405 ouvre une voie passionnante. Mais en 2026, vous devez composer avec ce qui existe déjà et qui a fait ses preuves. Et ce qui marche dépend d'abord de votre stade de chute.\n72\t\n73\tPour une perte débutante ou modérée, les traitements médicaux validés gardent toute leur place, comme on le détaille dans notre guide des [traitements contre la chute de cheveux qui fonctionnent vraiment](https://emrahcinik.com/fr/traitement-chute-cheveux-efficaces/). En parallèle, les soins régénératifs proposés en clinique stimulent déjà les follicules affaiblis. Le [PRP](https://emrahcinik.com/fr/medecine-capillaire/prp/), inclus dans tous les forfaits de greffe, relance la microcirculation. Les [exosomes](https://emrahcinik.com/fr/exosomes-cheveux/) apportent des centaines de facteurs de croissance. La [mésothérapie](https://emrahcinik.com/fr/mesotherapie-cheveux/) nourrit le cuir chevelu en profondeur.\n74\t\n75\tEt quand le follicule a disparu sur certaines zones, la seule réponse durable reste la greffe. Les techniques actuelles, qu'il s'agisse de la [FUE Saphir](https://emrahcinik.com/fr/greffe-de-cheveux/sapphire-fue/) ou de la [DHI](https://emrahcinik.com/fr/greffe-de-cheveux/dhi/), redéploient vos propres follicules là où il en faut, pour un résultat naturel et permanent. Le Dr Emrah Cinik, fort de plus de 20 ans d'expérience et de protocoles conformes aux standards ISHRS, examine chaque cuir chevelu pour orienter vers la bonne approche. Parfois c'est du médical, parfois c'est de la [greffe de cheveux en Turquie](https://emrahcinik.com/fr/), souvent c'est une combinaison des deux.\n76\t\n77\tN'hésitez pas à demander une [consultation](https://emrahcinik.com/fr/contact/) personnalisée gratuite. C'est le meilleur moyen d'y voir clair sur votre situation réelle, sans attendre une molécule encore en essai.\n78\t\n79\t## Références scientifiques\n80\t\n81\tFlores, A., Schell, J., Krall, A. S., Jelinek, D., Miranda, M., Grigorian, M., Braas, D., White, A. C., Zhou, J. L., Graham, N. A., Graeber, T., Seth, P., Evseenko, D., Coller, H. A., Rutter, J., Christofk, H. R., & Lowry, W. E. (2017). Lactate dehydrogenase activity drives hair follicle stem cell activation. *Nature Cell Biology*, *19*(9), 1017-1026. https://pubmed.ncbi.nlm.nih.gov/28812580/\n82\t\n83\tLiu, X., Wang, Y., Christofk, H. R., Lowry, W. E., & Jung, M. E. (2021). Development of novel mitochondrial pyruvate carrier inhibitors to treat hair loss. *Journal of Medicinal Chemistry*, *64*(4), 2046-2063. https://pubmed.ncbi.nlm.nih.gov/33534563/\n84\t\n85\tPelage Pharmaceuticals. (2025, 17 juin). *Pelage Pharmaceuticals announces positive phase 2a clinical trial results for PP405 in regenerative hair loss therapy* [Communiqué de presse]. Business Wire. https://www.businesswire.com/news/home/20250617338859/en/\n86\t\n87\tNational Library of Medicine. (2024). *A study to evaluate the safety, pharmacokinetics and efficacy of PP405 in androgenetic alopecia* (NCT06393452). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06393452\n88\t\n89\tHo, C. H., Sood, T., & Zito, P. M. (2024). *Androgenetic alopecia*. StatPearls. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/NBK430924/\n90\t\n91\tDermatology Times. (2025). *Pelage's PP405 demonstrates efficacy in phase 2a trial for androgenetic alopecia*. https://www.dermatologytimes.com/view/pelage-s-pp405-demonstrates-efficacy-in-phase-2a-trial-for-androgenetic-alopecia\n92\t\n93\t## Liens internes recommandés\n94\t\n95\t| Ancre suggérée | URL | Placement recommandé |\n96\t|---------------|-----|---------------------|\n97\t| finastéride | https://emrahcinik.com/fr/finasteride/ | Introduction |\n98\t| minoxidil | https://emrahcinik.com/fr/minoxidil/ | Introduction |\n99\t| calvitie héréditaire | https://emrahcinik.com/fr/calvitie-heredite/ | PP405 c'est quoi |\n100\t| alopécie androgénétique | https://emrahcinik.com/fr/alopecie-androgenetique/ | PP405 c'est quoi |\n101\t| médecine capillaire régénérative | https://emrahcinik.com/fr/medecine-capillaire-regenerative/ | PP405 c'est quoi |\n102\t| follicule pileux | https://emrahcinik.com/fr/follicules-pileux/ | Mécanisme |\n103\t| bloqueurs de DHT | https://emrahcinik.com/fr/bloqueurs-dht/ | Mécanisme |\n104\t| DHT | https://emrahcinik.com/fr/dht-chute-de-cheveux/ | Mécanisme |\n105\t| nouveaux médicaments contre la calvitie | https://emrahcinik.com/fr/nouveaux-medicaments-calvitie/ | Calendrier |\n106\t| clascotérone | https://emrahcinik.com/fr/clascoterone-cheveux/ | Calendrier |\n107\t| échelle de Norwood-Hamilton | https://emrahcinik.com/fr/norwood-hamilton/ | Limite |\n108\t| échelle de Ludwig | https://emrahcinik.com/fr/echelle-de-ludwig/ | Limite |\n109\t| calvitie complète | https://emrahcinik.com/fr/greffe-de-cheveux-calvitie-complete/ | Limite |\n110\t| zone donneuse | https://emrahcinik.com/fr/zone-donneuse-greffe-de-cheveux/ | Limite |\n111\t| cycle du cheveu | https://emrahcinik.com/fr/cycle-du-cheveu/ | Limite |\n112\t| traitements contre la chute de cheveux qui fonctionnent vraiment | https://emrahcinik.com/fr/traitement-chute-cheveux-efficaces/ | Solutions |\n113\t| PRP | https://emrahcinik.com/fr/medecine-capillaire/prp/ | Solutions |\n114\t| exosomes | https://emrahcinik.com/fr/exosomes-cheveux/ | Solutions |\n115\t| mésothérapie | https://emrahcinik.com/fr/mesotherapie-cheveux/ | Solutions |\n116\t| FUE Saphir | https://emrahcinik.com/fr/greffe-de-cheveux/sapphire-fue/ | Solutions |\n117\t| DHI | https://emrahcinik.com/fr/greffe-de-cheveux/dhi/ | Solutions |\n118\t| greffe de cheveux en Turquie | https://emrahcinik.com/fr/ | Solutions |\n119\t| consultation | https://emrahcinik.com/fr/contact/ | Solutions |\n120\t"}]},"uuid":"c6769500-b237-448d-956a-2e0336fad336","timestamp":"2026-06-01T09:32:56.656Z","sourceToolAssistantUUID":"1f34f977-13c7-4a37-b8ca-73a559383fb2","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"c6769500-b237-448d-956a-2e0336fad336","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_012V21fAkbseZZF49aYLVc2B","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01WsB1BS3bXYNGfdBThhUrvn","name":"Read","input":{"file_path":"/opt/automator/cinik-writer-transtor/files/_CONSIGNE_REVISION.md"},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":22792,"cache_creation_input_tokens":6157,"cache_read_input_tokens":4438,"cache_creation":{"ephemeral_5m_input_tokens":6157,"ephemeral_1h_input_tokens":0},"output_tokens":7,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":null},"requestId":"req_011CbcJtDT8NjwPxC3nLr3bX","attributionAgent":"general-purpose","type":"assistant","uuid":"2eb9e9cb-335e-43a6-a7c5-34f1f2307918","timestamp":"2026-06-01T09:32:57.129Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"2eb9e9cb-335e-43a6-a7c5-34f1f2307918","isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01WsB1BS3bXYNGfdBThhUrvn","type":"tool_result","content":"1\t# Consigne de révision + SEO (pour les réviseurs)\n2\t\n3\tTu révises UN article déjà rédigé pour le blog du Dr Emrah Cinik. Deux missions :\n4\t\n5\t## 1. Améliorer la fluidité et la qualité\n6\t- Lis l'article en entier. Repère les passages qui sonnent \"IA\", listes mécaniques, transitions plates, répétitions, paragraphes monotones.\n7\t- Réécris pour un rythme plus naturel : alterne phrases courtes qui claquent et phrases plus longues, fragments assumés, apartés conversationnels, métaphores vives. Ton Body Expert + Cinik (direct, \"vous\", \"ça\", affirmatif, chaleureux, vulgarisé).\n8\t- Améliore les accroches de section, fluidifie les enchaînements, supprime les tournures robotiques.\n9\t- Garde le fond INTACT : ne touche pas aux données chiffrées, aux sources, aux références APA, ni aux liens internes markdown (mêmes URLs, mêmes ancres ou ancres améliorées si plus naturelles). N'invente AUCUNE donnée ni source.\n10\t- **Gras pour la lisibilité** : mets du **gras** sur les chiffres clés, les termes importants et les idées fortes pour faciliter la lecture (sans en abuser, mais suffisamment pour que l'œil accroche).\n11\t- **Sources jamais citées en clair dans le corps** : retire toute citation entre parenthèses du type \"(Auteur et al., année)\". Fonds l'info en prose (\"une étude sur 2449 personnes a montré que...\"). MAIS garde la section \"Références scientifiques\" en APA en bas, intacte (avec ses URLs).\n12\t- **PAS de \"guide complet\"** ni formules creuses du même genre dans le H1/Title.\n13\t\n14\t## 2. Ajouter le bloc SEO en tête\n15\tAvant le H1, insère exactement ce bloc (puis une ligne `---`, puis le H1) :\n16\t\n17\t```\n18\t**Slug** : /slug-optimise\n19\t**Title SEO** : Titre accrocheur | Dr Cinik\n20\t**Meta description** : Phrase descriptive avec le mot-clé et une promesse.\n21\t\n22\t---\n23\t```\n24\t\n25\tRègles SEO :\n26\t- **Slug** : court, en minuscules, mots-clés, tirets. Sans /fr/ ni domaine. Ex : `/pp405-molecule-follicules` (ou simplement le mot-clé en slug propre).\n27\t- **Title SEO** : 60 caractères MAX (espaces inclus), mot-clé en début, finit par ` | Dr Cinik`.\n28\t- **Meta description** : 150-155 caractères MAX, inclut le mot-clé principal + une promesse éditoriale, donne envie de cliquer.\n29\t\n30\t## Règles de format absolues (inchangées)\n31\t- ZÉRO em dash (—) ni en dash (–). Vérifie avant de finir.\n32\t- Titres sans majuscule à chaque mot. Nombres sans séparateur de milliers. Gras avec parcimonie. Jamais de prix.\n33\t- Le fichier final = bloc SEO, puis `---`, puis `# H1`, puis l'article révisé (avec ses sections + la section \"Références scientifiques\" APA conservée).\n34\t- **SUPPRIME le tableau \"Liens internes recommandés\" en fin d'article.** Les liens internes restent dans le CORPS du texte (markdown), mais on ne veut PLUS ce tableau récapitulatif à la fin. Le fichier se termine donc par la section Références scientifiques.\n35\t- Pas de front-matter YAML.\n36\t"}]},"uuid":"43db4232-4a6c-4c3a-9e02-6b2eaac2ab24","timestamp":"2026-06-01T09:32:57.134Z","sourceToolAssistantUUID":"2eb9e9cb-335e-43a6-a7c5-34f1f2307918","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"43db4232-4a6c-4c3a-9e02-6b2eaac2ab24","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_012V21fAkbseZZF49aYLVc2B","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01NuyEAEPY43dBL4ASAuww5R","name":"Read","input":{"file_path":"/opt/automator/cinik-writer-transtor/files/_TON_CINIK.md"},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":22792,"cache_creation_input_tokens":6157,"cache_read_input_tokens":4438,"cache_creation":{"ephemeral_5m_input_tokens":6157,"ephemeral_1h_input_tokens":0},"output_tokens":7,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":null},"requestId":"req_011CbcJtDT8NjwPxC3nLr3bX","attributionAgent":"general-purpose","type":"assistant","uuid":"97c82928-3d8c-4783-8fd7-982f5de160ed","timestamp":"2026-06-01T09:32:58.084Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"97c82928-3d8c-4783-8fd7-982f5de160ed","isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01NuyEAEPY43dBL4ASAuww5R","type":"tool_result","content":"1\t# Brief de ton — blog Dr Emrah Cinik (analyse du site live, 2026-05-31)\n2\t\n3\t## Ton général\n4\tProfessionnel, rassurant, honnête, aspirationnel. Équilibre entre autorité médicale et bienveillance. La crédibilité vient de la **transparence** (on admet les limites et les échecs des traitements) plutôt que de la survente. Données cliniques précises + langage conversationnel qui démystifie.\n5\t\n6\t## Patterns de style à reproduire\n7\t- Phrases courtes qui claquent en titre, paragraphes de 2-4 phrases dans le corps. Alterner court/long pour le rythme.\n8\t- \"Vous\" omniprésent : \"vos follicules\", \"votre cuir chevelu\".\n9\t- Questions rhétoriques de guidage décisionnel (\"Quand la greffe devient-elle la bonne option ?\"), jamais commerciales (\"Pourquoi ne pas nous appeler ?\").\n10\t- Chiffres hyperspécifiques, jamais \"beaucoup\" : \"91 nouveaux cheveux contre 22\", \"1465 hommes dans 51 centres\". La précision = autorité.\n11\t- Honnêteté sur les limites : \"aucun traitement local ne fait repousser un follicule déjà mort\". Cette candeur renforce la confiance.\n12\t- Transitions causales : \"C'est précisément là qu'intervient...\", \"Autrement dit\", \"En clair\".\n13\t- Vulgariser TOUT terme technique à sa 1ʳᵉ apparition (DHT, alpha-réductase, follicule) avec une analogie courte.\n14\t\n15\t## Structure type d'un article\n16\t1. Intro : problème relatable + 1 stat de prévalence forte dans les 2 premières phrases.\n17\t2. Fondation éducative : mécanismes, anatomie, classification (vulgarisés).\n18\t3. Évaluation critique : ce que disent les études, résultats chiffrés, effets secondaires nommés et mis en perspective.\n19\t4. Considérations pratiques / guide patient.\n20\t5. Solutions (10% max) : transition naturelle vers les traitements Dr Cinik, sans survente.\n21\t\n22\t## À ÉVITER\n23\t- Jargon non expliqué dès la 1ʳᵉ mention.\n24\t- CTA agressifs trop tôt ; rester progressif et chaleureux.\n25\t- Superlatifs en rafale (\"ultra-moderne\", \"référence mondiale\" à chaque phrase) : ça dilue le poids.\n26\t- Critique trop tranchée d'un traitement concurrent (biais promo visible). Rester factuel.\n27\t- Em dash (—) et en dash (–) : INTERDITS, zéro tolérance.\n28\t- Mentionner des prix.\n29\t- Majuscule à chaque mot dans les titres.\n30\t"}]},"uuid":"8f887400-5921-405e-a2f0-bf26efb32b8c","timestamp":"2026-06-01T09:32:58.089Z","sourceToolAssistantUUID":"97c82928-3d8c-4783-8fd7-982f5de160ed","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"8f887400-5921-405e-a2f0-bf26efb32b8c","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_012V21fAkbseZZF49aYLVc2B","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_014zzRu6HagfS3GCLpDxQBVN","name":"ToolSearch","input":{"query":"select:WebFetch,WebSearch","max_results":5},"caller":{"type":"direct"}}],"stop_reason":"tool_use","stop_sequence":null,"stop_details":null,"usage":{"input_tokens":22792,"cache_creation_input_tokens":6157,"cache_read_input_tokens":4438,"output_tokens":346,"server_tool_use":{"web_search_requests":0,"web_fetch_requests":0},"service_tier":"standard","cache_creation":{"ephemeral_1h_input_tokens":0,"ephemeral_5m_input_tokens":6157},"inference_geo":"not_available","iterations":[{"input_tokens":22792,"output_tokens":346,"cache_read_input_tokens":4438,"cache_creation_input_tokens":6157,"cache_creation":{"ephemeral_5m_input_tokens":6157,"ephemeral_1h_input_tokens":0},"type":"message"}],"speed":"standard"},"diagnostics":null},"requestId":"req_011CbcJtDT8NjwPxC3nLr3bX","attributionAgent":"general-purpose","type":"assistant","uuid":"cea09181-3340-439c-bf4e-1b6aa64ba0c2","timestamp":"2026-06-01T09:32:58.424Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"cea09181-3340-439c-bf4e-1b6aa64ba0c2","isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":[{"type":"tool_result","tool_use_id":"toolu_014zzRu6HagfS3GCLpDxQBVN","content":[{"type":"tool_reference","tool_name":"WebFetch"},{"type":"tool_reference","tool_name":"WebSearch"}]}]},"uuid":"761d3fbc-867b-4a3b-a113-382a7c94f7ef","timestamp":"2026-06-01T09:32:58.428Z","sourceToolAssistantUUID":"cea09181-3340-439c-bf4e-1b6aa64ba0c2","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"761d3fbc-867b-4a3b-a113-382a7c94f7ef","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_01Kn1sF1AY4GDd84A9ZBPT2K","type":"message","role":"assistant","content":[{"type":"text","text":"Now let me analyze the competition and do research in parallel."}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":1740,"cache_creation_input_tokens":38618,"cache_read_input_tokens":4531,"cache_creation":{"ephemeral_5m_input_tokens":38618,"ephemeral_1h_input_tokens":0},"output_tokens":5,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":{"cache_miss_reason":{"type":"tools_changed","cache_missed_input_tokens":8996}}},"requestId":"req_011CbcJtcB7jm1nkZjaiMD8W","attributionAgent":"general-purpose","type":"assistant","uuid":"961068e4-2bb1-4786-950e-5dea13aef1bd","timestamp":"2026-06-01T09:33:00.745Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"961068e4-2bb1-4786-950e-5dea13aef1bd","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_01Kn1sF1AY4GDd84A9ZBPT2K","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_0176sLAccDA7Abiq5uK8vdE6","name":"WebFetch","input":{"url":"https://www.drserkanaygin.com/blog/pp405-hair-stem-cell-science-part-1/","prompt":"Summarize the key angles, sections, claims, data points, and depth covered in this article about PP405. List every distinct topic and any specific numbers/dates/mechanisms mentioned."},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":1740,"cache_creation_input_tokens":38618,"cache_read_input_tokens":4531,"cache_creation":{"ephemeral_5m_input_tokens":38618,"ephemeral_1h_input_tokens":0},"output_tokens":5,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":{"cache_miss_reason":{"type":"tools_changed","cache_missed_input_tokens":8996}}},"requestId":"req_011CbcJtcB7jm1nkZjaiMD8W","attributionAgent":"general-purpose","type":"assistant","uuid":"e1bc3d46-5da8-4c0f-92eb-64718a16856e","timestamp":"2026-06-01T09:33:02.764Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"e1bc3d46-5da8-4c0f-92eb-64718a16856e","isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_0176sLAccDA7Abiq5uK8vdE6","type":"tool_result","content":"The server returned HTTP 403 Forbidden.\n\nThe response body was not retrieved. If this URL requires authentication, use an authenticated tool (e.g. `gh` for GitHub, or an MCP-provided fetch tool) instead of WebFetch."}]},"uuid":"64d9acfb-a525-4403-83ae-0fea22f0206e","timestamp":"2026-06-01T09:33:02.940Z","sourceToolAssistantUUID":"e1bc3d46-5da8-4c0f-92eb-64718a16856e","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"64d9acfb-a525-4403-83ae-0fea22f0206e","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_01Kn1sF1AY4GDd84A9ZBPT2K","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01BJNjSP7jbfvGgcqoJosoe9","name":"WebFetch","input":{"url":"https://www.drserkanaygin.com/blog/pp405-hair-stem-cell-science-part-2/","prompt":"Summarize the key angles, sections, claims, data points, and depth covered in this article about PP405. List every distinct topic and any specific numbers/dates/mechanisms mentioned."},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":1740,"cache_creation_input_tokens":38618,"cache_read_input_tokens":4531,"cache_creation":{"ephemeral_5m_input_tokens":38618,"ephemeral_1h_input_tokens":0},"output_tokens":5,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":{"cache_miss_reason":{"type":"tools_changed","cache_missed_input_tokens":8996}}},"requestId":"req_011CbcJtcB7jm1nkZjaiMD8W","attributionAgent":"general-purpose","type":"assistant","uuid":"39c45039-78c5-46bd-ba93-9d2589acc4c9","timestamp":"2026-06-01T09:33:04.047Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"39c45039-78c5-46bd-ba93-9d2589acc4c9","isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01BJNjSP7jbfvGgcqoJosoe9","type":"tool_result","content":"The server returned HTTP 403 Forbidden.\n\nThe response body was not retrieved. If this URL requires authentication, use an authenticated tool (e.g. `gh` for GitHub, or an MCP-provided fetch tool) instead of WebFetch."}]},"uuid":"b19632f1-c168-48c3-8450-9ad4ce14ae61","timestamp":"2026-06-01T09:33:04.074Z","sourceToolAssistantUUID":"39c45039-78c5-46bd-ba93-9d2589acc4c9","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"b19632f1-c168-48c3-8450-9ad4ce14ae61","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_01Kn1sF1AY4GDd84A9ZBPT2K","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01BhdKYTnXrpMXiLz7owtyaL","name":"WebFetch","input":{"url":"https://www.drserkanaygin.com/blog/pp405-hair-stem-cell-science-part-3/","prompt":"Summarize the key angles, sections, claims, data points, and depth covered in this article about PP405. List every distinct topic and any specific numbers/dates/mechanisms mentioned."},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":1740,"cache_creation_input_tokens":38618,"cache_read_input_tokens":4531,"cache_creation":{"ephemeral_5m_input_tokens":38618,"ephemeral_1h_input_tokens":0},"output_tokens":5,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":{"cache_miss_reason":{"type":"tools_changed","cache_missed_input_tokens":8996}}},"requestId":"req_011CbcJtcB7jm1nkZjaiMD8W","attributionAgent":"general-purpose","type":"assistant","uuid":"b8e88036-35ff-4962-b6b7-bf8913ab4246","timestamp":"2026-06-01T09:33:04.972Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"b8e88036-35ff-4962-b6b7-bf8913ab4246","isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01BhdKYTnXrpMXiLz7owtyaL","type":"tool_result","content":"The server returned HTTP 403 Forbidden.\n\nThe response body was not retrieved. If this URL requires authentication, use an authenticated tool (e.g. `gh` for GitHub, or an MCP-provided fetch tool) instead of WebFetch."}]},"uuid":"ae7f0e2f-4f65-4ebd-aea7-df2dfab64602","timestamp":"2026-06-01T09:33:04.992Z","sourceToolAssistantUUID":"b8e88036-35ff-4962-b6b7-bf8913ab4246","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"ae7f0e2f-4f65-4ebd-aea7-df2dfab64602","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_01Kn1sF1AY4GDd84A9ZBPT2K","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01NhpLazAdJp55jWXjxSKTY6","name":"WebSearch","input":{"query":"PP405 Pelage Pharmaceuticals phase 2a results 2025 hair growth trial"},"caller":{"type":"direct"}}],"stop_reason":"tool_use","stop_sequence":null,"stop_details":null,"usage":{"input_tokens":1740,"cache_creation_input_tokens":38618,"cache_read_input_tokens":4531,"output_tokens":586,"server_tool_use":{"web_search_requests":0,"web_fetch_requests":0},"service_tier":"standard","cache_creation":{"ephemeral_1h_input_tokens":0,"ephemeral_5m_input_tokens":38618},"inference_geo":"not_available","iterations":[{"input_tokens":1740,"output_tokens":586,"cache_read_input_tokens":4531,"cache_creation_input_tokens":38618,"cache_creation":{"ephemeral_5m_input_tokens":38618,"ephemeral_1h_input_tokens":0},"type":"message"}],"speed":"standard"},"diagnostics":{"cache_miss_reason":{"type":"tools_changed","cache_missed_input_tokens":8996}}},"requestId":"req_011CbcJtcB7jm1nkZjaiMD8W","attributionAgent":"general-purpose","type":"assistant","uuid":"72bc1ea4-1e8e-4dde-8b63-7f5ee1908dec","timestamp":"2026-06-01T09:33:05.585Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"72bc1ea4-1e8e-4dde-8b63-7f5ee1908dec","isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01NhpLazAdJp55jWXjxSKTY6","type":"tool_result","content":"Web search results for query: \"PP405 Pelage Pharmaceuticals phase 2a results 2025 hair growth trial\"\n\nLinks: [{\"title\":\"What is PP405 (PP-405)? Clinical Update: Phase 2a Results, Safety & Release Date-2025 |Part 2| The REALITY\",\"url\":\"https://www.drserkanaygin.com/blog/pp405-clinical-trials-results-release-date/\"},{\"title\":\"News: BREAKING NEWS: PP405 Phase 2a Results: A New Frontier in Hair Follicle Regeneration\",\"url\":\"https://hairtransplantnetwork.com/breaking-news-pp405-phase-2a-results-new-frontier-hair-follicle-regeneration\"},{\"title\":\"Pelage's PP405 Demonstrates Efficacy in Phase 2a Trial for Androgenetic Alopecia | Dermatology Times\",\"url\":\"https://www.dermatologytimes.com/view/pelage-s-pp405-demonstrates-efficacy-in-phase-2a-trial-for-androgenetic-alopecia\"},{\"title\":\"Pelage Pharmaceuticals Announces $120 Million Series B Financing to Advance Regenerative Medicine Treatments for Hair Loss - Pelage\",\"url\":\"https://pelagepharma.com/press-releases/pelage-pharmaceuticals-announces-120-million-series-b-financing-to-advance-regenerative-medicine-treatments-for-hair-loss/\"},{\"title\":\"Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy - Pelage\",\"url\":\"https://pelagepharma.com/press-releases/pelage-pharmaceuticals-announces-positive-phase-2a-clinical-trial-results-for-pp405-in-regenerative-hair-loss-therapy/\"},{\"title\":\"Is pp405 Effective for Hair Loss Treatment? AlviArmani Articles\",\"url\":\"https://www.alviarmani.com/is-pp405-the-answer-to-hair-loss/\"},{\"title\":\"PP405 for Hair Loss – The Complete Guide 2026\",\"url\":\"https://xyonhealth.com/blogs/library/pp405-for-hair-loss\"}]\n\n## PP405 Phase 2a Results Summary\n\nIn mid-2025, Pelage Pharmaceuticals announced positive Phase 2a results, showing that the product was well-tolerated and produced measurable hair-density improvements in a subgroup of participants.\n\n**Key Efficacy Results:**\n\nAt week eight, 31% of men with a higher degree of hair loss treated with PP405 exhibited a greater than 20% increase in hair density, compared to 0% of patients responding in the placebo group.\n\n**Safety Profile:**\n\nPreliminary results showed that PP405 met the primary safety endpoint and was well tolerated with no systemic absorption of PP405 detected in the blood and no systemic adverse events.\n\n**Trial Details:**\n\nThe Phase 2a randomized controlled trial enrolled a total of 78 men and women with androgenetic alopecia, representing a diverse range of skin phototypes and hair textures.\n\n**Mechanism & Next Steps:**\n\nPP405 is designed to reactivate dormant hair follicle stem cells, offering a potential first-in-class approach for both men and women experiencing hair loss. The company plans larger Phase 3 studies for 2026.\n\n\nREMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks."}]},"uuid":"58fa11ec-f39c-4271-8fd4-3cf62ebd51ad","timestamp":"2026-06-01T09:33:11.984Z","sourceToolAssistantUUID":"72bc1ea4-1e8e-4dde-8b63-7f5ee1908dec","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"58fa11ec-f39c-4271-8fd4-3cf62ebd51ad","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_01K91193AizsA5iEUGb7XviM","type":"message","role":"assistant","content":[{"type":"text","text":"The Serkan Aygin URLs are 403. Let me fetch the competitor's actual reachable article and the key primary sources in parallel."}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":131,"cache_creation_input_tokens":3895,"cache_read_input_tokens":43149,"cache_creation":{"ephemeral_5m_input_tokens":3895,"ephemeral_1h_input_tokens":0},"output_tokens":1,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":null},"requestId":"req_011CbcJubsHks9XyfXkQLmXU","attributionAgent":"general-purpose","type":"assistant","uuid":"44b0da8c-edbc-4f7c-80b5-7ccf328210bc","timestamp":"2026-06-01T09:33:14.340Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"44b0da8c-edbc-4f7c-80b5-7ccf328210bc","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_01K91193AizsA5iEUGb7XviM","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01936ir1Ehz8uBxBoxG9fVYv","name":"WebFetch","input":{"url":"https://pelagepharma.com/press-releases/pelage-pharmaceuticals-announces-positive-phase-2a-clinical-trial-results-for-pp405-in-regenerative-hair-loss-therapy/","prompt":"Extract all specific facts: trial design, number of patients, dosing, duration, efficacy numbers, safety findings, quotes, dates, phase 3 plans, AAD presentation. Verbatim numbers and dates."},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":131,"cache_creation_input_tokens":3895,"cache_read_input_tokens":43149,"cache_creation":{"ephemeral_5m_input_tokens":3895,"ephemeral_1h_input_tokens":0},"output_tokens":1,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":null},"requestId":"req_011CbcJubsHks9XyfXkQLmXU","attributionAgent":"general-purpose","type":"assistant","uuid":"f4090864-50ad-48af-938e-d234840500c9","timestamp":"2026-06-01T09:33:16.698Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"f4090864-50ad-48af-938e-d234840500c9","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_01K91193AizsA5iEUGb7XviM","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_017CxnvARmK3drEGmNhkYFZZ","name":"WebFetch","input":{"url":"https://xyonhealth.com/blogs/library/pp405-for-hair-loss","prompt":"List every section/topic this guide covers about PP405, all data points, mechanism details, comparisons to minoxidil/finasteride, timeline, who benefits. What angles do they cover in depth?"},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":131,"cache_creation_input_tokens":3895,"cache_read_input_tokens":43149,"cache_creation":{"ephemeral_5m_input_tokens":3895,"ephemeral_1h_input_tokens":0},"output_tokens":1,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":null},"requestId":"req_011CbcJubsHks9XyfXkQLmXU","attributionAgent":"general-purpose","type":"assistant","uuid":"73e27617-9afd-41e9-87e7-df591d5f22d7","timestamp":"2026-06-01T09:33:18.123Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"73e27617-9afd-41e9-87e7-df591d5f22d7","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_01K91193AizsA5iEUGb7XviM","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01Kt469bCsu5kHkFLkGb1Gyy","name":"WebFetch","input":{"url":"https://www.dermatologytimes.com/view/pelage-s-pp405-demonstrates-efficacy-in-phase-2a-trial-for-androgenetic-alopecia","prompt":"Extract all specific facts and numbers about the PP405 phase 2a trial, mechanism, dosing, and timeline."},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":131,"cache_creation_input_tokens":3895,"cache_read_input_tokens":43149,"cache_creation":{"ephemeral_5m_input_tokens":3895,"ephemeral_1h_input_tokens":0},"output_tokens":1,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":null},"requestId":"req_011CbcJubsHks9XyfXkQLmXU","attributionAgent":"general-purpose","type":"assistant","uuid":"792fc353-dc34-44a1-8f3f-30def76aa8f9","timestamp":"2026-06-01T09:33:19.524Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"792fc353-dc34-44a1-8f3f-30def76aa8f9","isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01Kt469bCsu5kHkFLkGb1Gyy","type":"tool_result","content":"The server returned HTTP 403 Forbidden.\n\nThe response body was not retrieved. If this URL requires authentication, use an authenticated tool (e.g. `gh` for GitHub, or an MCP-provided fetch tool) instead of WebFetch."}]},"uuid":"c707d0cd-4239-43f1-a7cd-a0ae9c362589","timestamp":"2026-06-01T09:33:19.713Z","sourceToolAssistantUUID":"792fc353-dc34-44a1-8f3f-30def76aa8f9","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"c707d0cd-4239-43f1-a7cd-a0ae9c362589","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_01K91193AizsA5iEUGb7XviM","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01PSdWDp22sVfEXyVbj3DJvu","name":"WebSearch","input":{"query":"PP405 phase 3 trial 2026 start date AAD presentation timeline Pelage"},"caller":{"type":"direct"}}],"stop_reason":"tool_use","stop_sequence":null,"stop_details":null,"usage":{"input_tokens":131,"cache_creation_input_tokens":3895,"cache_read_input_tokens":43149,"output_tokens":660,"server_tool_use":{"web_search_requests":0,"web_fetch_requests":0},"service_tier":"standard","cache_creation":{"ephemeral_1h_input_tokens":0,"ephemeral_5m_input_tokens":3895},"inference_geo":"not_available","iterations":[{"input_tokens":131,"output_tokens":660,"cache_read_input_tokens":43149,"cache_creation_input_tokens":3895,"cache_creation":{"ephemeral_5m_input_tokens":3895,"ephemeral_1h_input_tokens":0},"type":"message"}],"speed":"standard"},"diagnostics":null},"requestId":"req_011CbcJubsHks9XyfXkQLmXU","attributionAgent":"general-purpose","type":"assistant","uuid":"1bcce48f-9d4c-4c48-9e72-3986e39c6a0a","timestamp":"2026-06-01T09:33:19.946Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"f4090864-50ad-48af-938e-d234840500c9","isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01936ir1Ehz8uBxBoxG9fVYv","type":"tool_result","content":"# PP405 Phase 2a Trial: Key Facts\n\n**Trial Design & Patient Population**\n- Randomized controlled trial with 78 participants (men and women)\n- Diverse skin phototypes and hair textures represented\n- Diagnosis: androgenetic alopecia\n\n**Dosing & Duration**\n- Topical application once daily for 4 weeks\n- Follow-up assessment extended to 12 weeks\n\n**Efficacy Results**\n- Week 8 (4 weeks post-treatment completion): 31% of higher hair loss men showed >20% hair density increase vs. 0% placebo\n- New hair growth observed from previously inactive follicles\n- Faster response than typical 6-12 month timeframe for existing treatments\n\n**Safety Findings**\n- Met primary safety endpoint\n- No systemic blood absorption detected\n- Well tolerated\n- Open-label 3-month safety extension offered to placebo recipients\n\n**Key Quote**\n\"These early clinical results reinforce the potential of our approach to go beyond slowing hair loss and directly drive hair follicle regeneration.\" — Dr. Christina Weng, CMO\n\n**Timeline**\n- Trial announcement: June 17, 2025\n- Phase 3 initiation planned: 2026\n\n**Mechanism**\nReactivates dormant hair follicle stem cells via metabolic pathway targeting"}]},"uuid":"a2853680-0019-411a-9357-a01d6f850f3b","timestamp":"2026-06-01T09:33:22.429Z","sourceToolAssistantUUID":"f4090864-50ad-48af-938e-d234840500c9","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"73e27617-9afd-41e9-87e7-df591d5f22d7","isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_017CxnvARmK3drEGmNhkYFZZ","type":"tool_result","content":"# PP405 Guide: Sections and Coverage\n\n## Major Topics Covered\n\n**What PP405 Is**\n- Investigational topical therapy by Pelage Pharmaceuticals for androgenetic alopecia\n- Described as capable of \"regenerate near-dormant hair follicles\"\n\n**Mechanism of Action**\n- Functions as a mitochondrial pyruvate carrier (MPC)\n- Increases lactate and energy at hair follicles via stem cell activation\n- Theoretically switches follicles from dormant to active growth phase\n\n**Clinical Trial Data (Phase 2a)**\n- 78 participants in randomized, placebo-controlled study\n- 4-week dosing period with ~12-week follow-up\n- Primary focus: safety and pharmacokinetics\n- No peer-reviewed published results yet\n\n**Availability & Access**\n- Not FDA-approved or commercially available\n- Only legitimate access through official clinical trials\n- Warns against purchasing online products\n\n**Safety Profile**\n- Major unknowns: long-term side effects, delayed effects, frequency, age factors\n- Insufficient long-term testing data\n\n**Comparison to Established Treatments**\n- Finasteride: decades of studies, well-documented side effects\n- Dutasteride: extensive data supporting efficacy\n- Minoxidil: over-the-counter, extensively tested\n- Conclusion: current evidence still favors DHT suppression and growth-phase support\n\n**Timeline Projections**\n- Phase 3 advancement planned for 2026\n- Estimated market availability: 2028-2029\n\n**Biology Nuance**\n- Clarifies follicles miniaturize rather than \"die\" in AGA\n- Stem cell populations remain in bald scalp, offering regeneration potential\n\n**When to Start Treatment**\n- Recommends beginning available medications now rather than waiting\n- Emphasizes early intervention preserves follicles better"}]},"uuid":"beb78807-b65f-496a-96d5-cad89b38fd7e","timestamp":"2026-06-01T09:33:24.625Z","sourceToolAssistantUUID":"73e27617-9afd-41e9-87e7-df591d5f22d7","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"1bcce48f-9d4c-4c48-9e72-3986e39c6a0a","isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01PSdWDp22sVfEXyVbj3DJvu","type":"tool_result","content":"Web search results for query: \"PP405 phase 3 trial 2026 start date AAD presentation timeline Pelage\"\n\nLinks: [{\"title\":\"Pelage Pharmaceuticals Phase 3 Trials for PP405 in 2026 | Hair Loss Cure 2020\",\"url\":\"https://www.hairlosscure2020.com/pelage-pharmaceuticals-clinical-trials/\"},{\"title\":\"Pelage\",\"url\":\"https://pelagepharma.com/\"},{\"title\":\"Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026 - Pelage\",\"url\":\"https://pelagepharma.com/press-releases/pelage-pp405-aad-2026/\"},{\"title\":\"Pelage Pharmaceuticals Phase 3 Trials for PP405 in 2026\",\"url\":\"https://www.hairlosscure2020.com/category/pp405/\"},{\"title\":\"PP405 Hair Loss Treatment: Trials, Mechanism & Timeline\",\"url\":\"https://www.hermestclinic.com/pp405/\"},{\"title\":\"Pelage Pharmaceuticals Announces $120 Million Series B Financing to Advance Regenerative Medicine Treatments for Hair Loss - Pelage\",\"url\":\"https://pelagepharma.com/press-releases/pelage-pharmaceuticals-announces-120-million-series-b-financing-to-advance-regenerative-medicine-treatments-for-hair-loss/\"},{\"title\":\"PP405 - Wikipedia\",\"url\":\"https://en.wikipedia.org/wiki/PP405\"},{\"title\":\"Pelage's PP405 Demonstrates Efficacy in Phase 2a Trial for Androgenetic Alopecia | Dermatology Times\",\"url\":\"https://www.dermatologytimes.com/view/pelage-s-pp405-demonstrates-efficacy-in-phase-2a-trial-for-androgenetic-alopecia\"}]\n\nBased on the search results, here's what I found about PP405, Pelage Pharmaceuticals' phase 3 trial timeline, and their AAD presentation:\n\n## Phase 3 Trial Timeline\nPelage expects to initiate late-stage studies in 2026, designed to further evaluate the safety and efficacy of PP405 in patients with androgenetic alopecia.\n\n## AAD Presentation Details\nThe presentation is scheduled for Saturday, March 28 at 10:15 a.m., titled \"Emerging treatments for hair loss targeting dormant follicles,\" with presenter Arash Mostaghimi, M.D., MPH, FAAD from Brigham and Women's Hospital and Harvard Medical School.\n\n## Recent Progress\nThe company previously reported Phase 2a topline results in which PP405 was well tolerated in men and women with no systemic absorption. While dosing was limited to four weeks, results in men with a higher degree of hair loss showed a rapid and significant clinical response by week eight, with new terminal hair demonstrated to grow from previously dormant follicular units.\n\n## Future Approval Timeline\nIf PP405 is successful in clinical trials and passes regulatory scrutiny, the drug could be approved for the treatment of hair loss sometime between 2027 and 2029 at the earliest.\n\n\nREMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks."}]},"uuid":"a2bea0f3-cb4a-49d3-8702-b848648d525d","timestamp":"2026-06-01T09:33:27.587Z","sourceToolAssistantUUID":"1bcce48f-9d4c-4c48-9e72-3986e39c6a0a","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"a2bea0f3-cb4a-49d3-8702-b848648d525d","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_01QhLXFKU4VgCgWyV18ejpCe","type":"message","role":"assistant","content":[{"type":"text","text":"Good data. Let me get the competitor depth (Serkan Aygin via Google cache approach isn't possible; I'll use their search snippet which I have) and round out research on competing innovations and comparisons."}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":2,"cache_creation_input_tokens":3232,"cache_read_input_tokens":47044,"cache_creation":{"ephemeral_5m_input_tokens":3232,"ephemeral_1h_input_tokens":0},"output_tokens":3,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":null},"requestId":"req_011CbcJvkYTSUmCeTPyWzSBS","attributionAgent":"general-purpose","type":"assistant","uuid":"6ca10f5c-f434-43a5-a038-6f1f5ba685aa","timestamp":"2026-06-01T09:33:31.046Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"6ca10f5c-f434-43a5-a038-6f1f5ba685aa","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_01QhLXFKU4VgCgWyV18ejpCe","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01NfPiPsDZB5t7iMapAubWyd","name":"WebFetch","input":{"url":"https://en.wikipedia.org/wiki/PP405","prompt":"Extract all verified facts: discovery, UCLA researchers, mechanism (MPC1/MPC2, lactate, LDH), trial phases, dosing, patients, results, funding, Pelage history, timeline, any phase 1 details."},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":2,"cache_creation_input_tokens":3232,"cache_read_input_tokens":47044,"cache_creation":{"ephemeral_5m_input_tokens":3232,"ephemeral_1h_input_tokens":0},"output_tokens":3,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":null},"requestId":"req_011CbcJvkYTSUmCeTPyWzSBS","attributionAgent":"general-purpose","type":"assistant","uuid":"6f02e503-35b3-462c-832e-de20bf403534","timestamp":"2026-06-01T09:33:32.454Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"6f02e503-35b3-462c-832e-de20bf403534","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_01QhLXFKU4VgCgWyV18ejpCe","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_012tmKRbsBY2s5QmoMXbSrFs","name":"WebFetch","input":{"url":"https://pelagepharma.com/press-releases/pelage-pp405-aad-2026/","prompt":"Extract all facts about the AAD 2026 presentation, phase 3 plans, dates, presenters, and any new data points or quotes."},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":2,"cache_creation_input_tokens":3232,"cache_read_input_tokens":47044,"cache_creation":{"ephemeral_5m_input_tokens":3232,"ephemeral_1h_input_tokens":0},"output_tokens":3,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":null},"requestId":"req_011CbcJvkYTSUmCeTPyWzSBS","attributionAgent":"general-purpose","type":"assistant","uuid":"5ac71452-5093-4c89-b179-4e4add457517","timestamp":"2026-06-01T09:33:33.907Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"5ac71452-5093-4c89-b179-4e4add457517","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_01QhLXFKU4VgCgWyV18ejpCe","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01N1pMA1wjPTg2nut2HbUgER","name":"WebSearch","input":{"query":"verteporfin hair regeneration trial 2025 scarless wound stemson exosomes hair cloning latest"},"caller":{"type":"direct"}}],"stop_reason":"tool_use","stop_sequence":null,"stop_details":null,"usage":{"input_tokens":2,"cache_creation_input_tokens":3232,"cache_read_input_tokens":47044,"output_tokens":456,"server_tool_use":{"web_search_requests":0,"web_fetch_requests":0},"service_tier":"standard","cache_creation":{"ephemeral_1h_input_tokens":0,"ephemeral_5m_input_tokens":3232},"inference_geo":"not_available","iterations":[{"input_tokens":2,"output_tokens":456,"cache_read_input_tokens":47044,"cache_creation_input_tokens":3232,"cache_creation":{"ephemeral_5m_input_tokens":3232,"ephemeral_1h_input_tokens":0},"type":"message"}],"speed":"standard"},"diagnostics":null},"requestId":"req_011CbcJvkYTSUmCeTPyWzSBS","attributionAgent":"general-purpose","type":"assistant","uuid":"002a39ef-1b74-41f6-9159-0239f7c53c49","timestamp":"2026-06-01T09:33:34.742Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"5ac71452-5093-4c89-b179-4e4add457517","isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_012tmKRbsBY2s5QmoMXbSrFs","type":"tool_result","content":"# AAD 2026 Presentation Facts\n\n## Presentation Details\n- **Event:** American Academy of Dermatology Annual Meeting 2026\n- **Location:** Denver, Colorado\n- **Date & Time:** Saturday, March 28, 2026 at 10:15 a.m. MST\n- **Session:** S020 New Innovations in Dermatology: What Devices and Treatments You Will Be Using in the Next 1-5 Years\n- **Topic:** Emerging treatments for hair loss targeting dormant follicles\n\n## Presenter\n**Arash Mostaghimi, M.D., MPH, FAAD**\n- Vice Chair of Clinical Trials and Innovation, Brigham and Women's Hospital\n- Associate Professor, Harvard Medical School\n\n## Key Finding\nThe presentation will highlight PP405's approach of targeting \"dormant hair follicle stem cells.\" The drug aims to activate previously inactive follicular units—a capability differentiated from existing treatments that focus on already-active follicles.\n\n## Phase 2a Results\n- Well tolerated in men and women\n- No systemic absorption observed\n- Treatment limited to four weeks\n- Men with greater hair loss showed \"rapid and significant clinical response by week eight, four weeks after treatment completion\"\n- New terminal hair emerged from previously dormant follicular units\n\n## Future Development\n\"Pelage expects to initiate late-stage studies in 2026\" to further evaluate PP405's safety and efficacy for androgenetic alopecia."}]},"uuid":"dedcf771-c608-432e-b973-5468b48a5adf","timestamp":"2026-06-01T09:33:40.112Z","sourceToolAssistantUUID":"5ac71452-5093-4c89-b179-4e4add457517","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"6f02e503-35b3-462c-832e-de20bf403534","isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01NfPiPsDZB5t7iMapAubWyd","type":"tool_result","content":"# PP405: Verified Facts from Wikipedia\n\n## Discovery & Origins\nPP405 originated at UCLA and was developed by Pelage Pharmaceuticals, founded in 2018 by three UCLA scientists: Bill Lowry, Heather Christofk, and Michael Jung. Lab work had been ongoing for \"almost a decade\" as of 2025.\n\n## Mechanism of Action\nPP405 is a dual mitochondrial pyruvate carrier (MPC1/MPC2) inhibitor. It works by causing pyruvate accumulation, which stimulates lactate dehydrogenase (LDH) activity in hair follicle stem cells. This increases lactic acid and glycolysis, providing more cellular energy for growth. High lactate levels correlate with the active anagen growth phase, while low levels correspond to dormant telogen phase.\n\n## Clinical Development\n- **Phase 1**: Completed\n- **Phase 2a**: Completed; data released June 2025\n- **Phase 2b**: Ongoing as of June 2025\n- **Phase 3**: Planned for 2026\n- **First human trials**: Started 2023 in Orange County, California\n\n## Phase 2a Results\nIn the preliminary trial, \"31% of men with advanced baldness experienced an increase in hair density of 20% or more at the 8-week follow-up.\" The placebo group showed no improvement. New hair was described as \"thick terminal hair\" rather than vellus hair, though before-and-after photos were not shared.\n\n## Dosing\n0.05% gel applied topically to scalp once daily\n\n## Key Pharmacokinetic Feature\nNo PP405 was detected in circulation during topical administration, limiting systemic side effects.\n\n## Funding\n- Over $30 million raised by August 2025 (led by Google Ventures)\n- $120 million Series B announced October 2025\n\n## Company Leadership\nChief Medical Officer: Qing Yu Christina Weng\n\n## Limitations\nThe drug may not be effective if hair follicles are permanently scarred in advanced baldness stages. Efficacy requires follicles to be intact and merely dormant.\n\n## Recognition\nNamed one of the best inventions of 2025 by *Time* magazine (October 2025)\n\n## Important Clarification\nPelage explicitly states PP405 is neither JXL069 nor JXL082, despite online speculation otherwise."}]},"uuid":"be7bdbf8-7377-4dbb-9ff6-74e0f825a630","timestamp":"2026-06-01T09:33:41.631Z","sourceToolAssistantUUID":"6f02e503-35b3-462c-832e-de20bf403534","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"002a39ef-1b74-41f6-9159-0239f7c53c49","isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01N1pMA1wjPTg2nut2HbUgER","type":"tool_result","content":"Web search results for query: \"verteporfin hair regeneration trial 2025 scarless wound stemson exosomes hair cloning latest\"\n\nLinks: [{\"title\":\"Verteporfin - Tressless\",\"url\":\"https://tressless.com/learn/verteporfin\"},{\"title\":\"Hair Multiplication Hair Stem Cells Treatment – Hair Restoration News Worldwide\",\"url\":\"https://hairsite.com/hair-multiplication-hair-stem-cells-treatment/\"},{\"title\":\"Use of Verteporfin with Dermal Wounding to Regenerate New Hair in Androgenetic Alopecia\",\"url\":\"https://clinmedjournals.org/articles/ijdrt/journal-of-dermatology-research-and-therapy-ijdrt-11-133.php?jid=ijdrt\"},{\"title\":\"(PDF) Use of Verteporfin to Regrow Hair and Reduce Fibrosis after Transplantation\",\"url\":\"https://www.researchgate.net/publication/394866426_Use_of_Verteporfin_to_Regrow_Hair_and_Reduce_Fibrosis_after_Transplantation\"},{\"title\":\"Is Hair Cloning the Future of Hair Restoration - Stemsontx\",\"url\":\"https://stemsontx.com/hair-cloning/\"},{\"title\":\"Verteporfin in Hair Transplant Surgery: A Paradigm Shift Towards Scarless Healing and Unlimited Donor Potential - American Hair Loss Association\",\"url\":\"https://www.americanhairloss.org/verteporfin-in-hair-transplant-surgery/\"},{\"title\":\"Therapeutic potential of stem cell-derived exosomes in hair regeneration: A systematic review - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12305264/\"}]\n\nBased on the search results, here's what the latest research shows on these hair regeneration approaches:\n\n## Verteporfin and Hair Regeneration\n\nVerteporfin human clinical trials for hair loss may start in 2025. Recent Stanford research has revealed a novel use for verteporfin promoting scarless skin regeneration by inhibition of Yes-associated protein (YAP), preventing the activation of En1-positive fibroblasts causing scars. Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles.\n\nA recent 2025 study published in the Journal of Dermatology Research and Therapy evaluated two male subjects aged 35 and 48 with androgenetic alopecia and history of remote (>3 years) FUE hair transplant seeking de novo hair growth without additional hair transplant.\n\n## Hair Cloning and Stemson\n\nAs of 2025, hair cloning is still in the experimental phase, but research, clinical trials, and follicle banking programs are making steady progress. If successful, hair cloning could mean natural results without surgery or scars. Companies like HairClone (UK) and Stemson Therapeutics (U.S.) are pioneering early human trials, including follicle banking and bioengineered grafts.\n\n## Exosome Therapy\n\nExosome therapy, derived from stem cells, helps stimulate follicle repair and growth by delivering growth signals to target areas. Exosome-based therapies represent a promising approach for hair regeneration. Unlike conventional treatments such as minoxidil and finasteride, exosomes deliver bioactive cargo that can stimulate dermal papilla cells, enhance angiogenesis, and modulate inflammatory pathways.\n\n\nREMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks."}]},"uuid":"b8320788-e0bc-4fc2-ba1c-49e8caa4ff1d","timestamp":"2026-06-01T09:33:42.767Z","sourceToolAssistantUUID":"002a39ef-1b74-41f6-9159-0239f7c53c49","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"b8320788-e0bc-4fc2-ba1c-49e8caa4ff1d","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_01NegWX8MghSmJpgiZafnSg7","type":"message","role":"assistant","content":[{"type":"text","text":"I have strong, verified data. Let me try one Google-cached read of the Serkan Aygin competitor structure via a search to understand their 3-part angle coverage, then write."}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":2,"cache_creation_input_tokens":3067,"cache_read_input_tokens":50276,"cache_creation":{"ephemeral_5m_input_tokens":3067,"ephemeral_1h_input_tokens":0},"output_tokens":2,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":null},"requestId":"req_011CbcJwsTi5vkMdb7Bdhx7F","attributionAgent":"general-purpose","type":"assistant","uuid":"d4f76623-76ee-4bc9-86c0-39b9584c0046","timestamp":"2026-06-01T09:33:45.549Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"d4f76623-76ee-4bc9-86c0-39b9584c0046","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_01NegWX8MghSmJpgiZafnSg7","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_016zbYm6224rfP6fpBfR2Sja","name":"WebSearch","input":{"query":"drserkanaygin PP405 hair stem cell science part 1 part 2 part 3 sections topics covered"},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":2,"cache_creation_input_tokens":3067,"cache_read_input_tokens":50276,"cache_creation":{"ephemeral_5m_input_tokens":3067,"ephemeral_1h_input_tokens":0},"output_tokens":2,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":null},"requestId":"req_011CbcJwsTi5vkMdb7Bdhx7F","attributionAgent":"general-purpose","type":"assistant","uuid":"6693cc7e-6808-40b1-8a2d-6d7d06ab18f5","timestamp":"2026-06-01T09:33:46.493Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"6693cc7e-6808-40b1-8a2d-6d7d06ab18f5","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_01NegWX8MghSmJpgiZafnSg7","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_013W2J7fagYyFcXJFfyS2TR3","name":"WebFetch","input":{"url":"https://www.hairlosscure2020.com/pelage-pharmaceuticals-clinical-trials/","prompt":"Extract any verified details on PP405 phase 1, phase 2a, phase 2b, phase 3 design, patient numbers, dosing changes, and timeline beyond what is public. Note anything about longer dosing in future trials."},"caller":{"type":"direct"}}],"stop_reason":"tool_use","stop_sequence":null,"stop_details":null,"usage":{"input_tokens":2,"cache_creation_input_tokens":3067,"cache_read_input_tokens":50276,"output_tokens":316,"server_tool_use":{"web_search_requests":0,"web_fetch_requests":0},"service_tier":"standard","cache_creation":{"ephemeral_1h_input_tokens":0,"ephemeral_5m_input_tokens":3067},"inference_geo":"not_available","iterations":[{"input_tokens":2,"output_tokens":316,"cache_read_input_tokens":50276,"cache_creation_input_tokens":3067,"cache_creation":{"ephemeral_5m_input_tokens":3067,"ephemeral_1h_input_tokens":0},"type":"message"}],"speed":"standard"},"diagnostics":null},"requestId":"req_011CbcJwsTi5vkMdb7Bdhx7F","attributionAgent":"general-purpose","type":"assistant","uuid":"0de893d6-d207-471b-b14b-b17801552547","timestamp":"2026-06-01T09:33:48.262Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"0de893d6-d207-471b-b14b-b17801552547","isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_013W2J7fagYyFcXJFfyS2TR3","type":"tool_result","content":"# PP405 Clinical Trial Details\n\n## Phase 1\n- **Safety focus**: Demonstrated safety and proof of mechanism\n- **Outcome**: \"Statistically significant stem cell activation in hair follicles after one week of treatment\"\n\n## Phase 2a\n- **Participants**: 78 men and women with androgenetic alopecia\n- **Duration**: 4 weeks of treatment, followed to 12 weeks\n- **Frequency**: Daily application (topical gel)\n- **Results**: New hair growth from previously inactive follicles; 31% showed >20% hair density increase vs. 0% placebo\n- **Safety**: No adverse events or toxicity observed\n\n## Phase 2b\n- **Status**: Completed late 2025\n- **Design**: Open-label extension with 3 months of treatment\n- **Data release**: Planned for future 2026 medical meeting (not presented at AAD March 2026)\n\n## Phase 3\n- **Timeline**: Expected to initiate \"in coming months\" (as of May 2026)\n- **Requirement**: 6-month washout from prior AGA treatments (minoxidil/finasteride)\n- **Expected duration**: Approximately 1 year trial length\n\n## Dosing Changes\nThe article mentions Phase 2a used only 28-day exposure with 4-week follow-up. Phase 3 design details regarding extended duration remain unconfirmed, though longer application periods are anticipated to potentially improve outcomes."}]},"uuid":"dbfe7b64-22c8-411e-bcb5-13c3b4bd1079","timestamp":"2026-06-01T09:33:57.209Z","sourceToolAssistantUUID":"0de893d6-d207-471b-b14b-b17801552547","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"6693cc7e-6808-40b1-8a2d-6d7d06ab18f5","isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_016zbYm6224rfP6fpBfR2Sja","type":"tool_result","content":"Web search results for query: \"drserkanaygin PP405 hair stem cell science part 1 part 2 part 3 sections topics covered\"\n\nLinks: [{\"title\":\"What is PP405 (PP-405)? How It Wakes Up Dormant Hair Stem Cells |Part 1| The SCIENCE\",\"url\":\"https://www.drserkanaygin.com/blog/pp405-hair-stem-cell-science-part-1/\"},{\"title\":\"PP405: Revolutionary Hair Restoration Breakthrough - Hair GP\",\"url\":\"https://hairgp.co.uk/pp405-revolutionary-hair-restoration-breakthrough/\"},{\"title\":\"PP405: a new approach to reactivating hair growth?\",\"url\":\"https://aneeq.co/blog/pp405-a-new-approach-to-reactivating-hair-growth/\"},{\"title\":\"A New Way to Regrow Hair? Inside the Science of PP-405\",\"url\":\"https://perfecthairhealth.com/a-new-way-to-regrow-hair-inside-the-science-of-pp-405/\"},{\"title\":\"PP405: The Breakthrough Stem Cell Technology That Could Redefine Hair Restoration and Rejuvenation\",\"url\":\"https://parsamohebi.com/pp405-the-breakthrough-stem-cell-technology-that-could-redefine-hair-restoration/\"},{\"title\":\"Breakthrough Hair Loss Treatment | UCLA’s PP405 Discovery\",\"url\":\"https://revitaltrichology.com/breakthrough-in-hair-loss-treatment-uclas-discovery-pp405/\"},{\"title\":\"PP405 for Hair Loss: What the 2026 Science Really Shows | National Stem Cell Therapy\",\"url\":\"https://nationalstemcelltherapy.com/pp405-for-hair-loss-what-the-2026-science-really-shows/\"}]\n\nLet me search for more specific information about the different parts of the Dr. Serkan Aygin's series:\n\nLinks: [{\"title\":\"What is PP405 (PP-405)? How It Wakes Up Dormant Hair Stem Cells |Part 1| The SCIENCE\",\"url\":\"https://www.drserkanaygin.com/blog/pp405-hair-stem-cell-science-part-1/\"},{\"title\":\"What is PP405 (PP-405)? Clinical Update: Phase 2a Results, Safety & Release Date-2025 |Part 2| The REALITY\",\"url\":\"https://www.drserkanaygin.com/blog/pp405-clinical-trials-results-release-date/\"},{\"title\":\"PP405 for Hair Loss: What the 2026 Science Really Shows | National Stem Cell Therapy\",\"url\":\"https://nationalstemcelltherapy.com/pp405-for-hair-loss-what-the-2026-science-really-shows/\"},{\"title\":\"PP405: Revolutionary Hair Restoration Breakthrough - Hair GP\",\"url\":\"https://hairgp.co.uk/pp405-revolutionary-hair-restoration-breakthrough/\"},{\"title\":\"PP405: a new approach to reactivating hair growth?\",\"url\":\"https://aneeq.co/blog/pp405-a-new-approach-to-reactivating-hair-growth/\"},{\"title\":\"PP405: The Breakthrough Stem Cell Technology That Could Redefine Hair Restoration and Rejuvenation\",\"url\":\"https://parsamohebi.com/pp405-the-breakthrough-stem-cell-technology-that-could-redefine-hair-restoration/\"},{\"title\":\"PP405 Hair Loss Treatment: Trials, Mechanism & Timeline\",\"url\":\"https://www.hermestclinic.com/pp405/\"}]\n\nNow let me search for information about Part 3:\n\nLinks: [{\"title\":\"What is PP405 (PP-405)? How It Wakes Up Dormant Hair Stem Cells |Part 1| The SCIENCE\",\"url\":\"https://www.drserkanaygin.com/blog/pp405-hair-stem-cell-science-part-1/\"},{\"title\":\"What Is PP405 Hair Loss Treatment? | Cosmedica\",\"url\":\"https://cosmedica.com/pp405-hair-loss-treatment/\"},{\"title\":\"What is PP405 (PP-405)? Clinical Update: Phase 2a Results, Safety & Release Date-2025 |Part 2| The REALITY\",\"url\":\"https://www.drserkanaygin.com/blog/pp405-clinical-trials-results-release-date/\"},{\"title\":\"Regenerative Medicine in Action: Topical PP405 Shows Promise in Androgenetic Alopecia - The Dermatology Digest\",\"url\":\"https://thedermdigest.com/regenerative-medicine-in-action-topical-pp405-shows-promise-in-androgenetic-alopecia/\"},{\"title\":\"PP405 - Tressless\",\"url\":\"https://tressless.com/learn/pp405\"}]\n\nBased on the search results, I found information about the Dr. Serkan Aygin PP405 series. Here's what the different parts cover:\n\n## Dr. Serkan Aygin PP405 Hair Stem Cell Science Series\n\n**Part 1 (PP405 – The Science)**: Focuses on how PP405 works (mitochondria vs. hormones), the UCLA origin story, and why it's a scientific breakthrough. Key topics covered in Part 1 include:\n- PP405 is a topical small-molecule drug designed to reactivate dormant hair follicle stem cells\n- How it works on a cellular level by inhibiting a specific transporter in your cells' mitochondria, flipping a biological switch from \"rest\" to \"growth\"\n- MPC (Mitochondrial Pyruvate Carrier) and how blocking it forces the cell to produce lactate, which signals stem cells that \"it's time to grow\"\n\n**Part 2 (PP405 – The Reality)**: Focuses on the results (31% growth in Phase 2a), the release date (2028), safety data, and immediate alternatives. Key topics in Part 2 include:\n- 31% of patients treated with a 0.05% topical PP405 gel saw a greater than 20% increase in hair density after just 8 weeks of daily use\n- PP405 showed evidence of inducing new hair growth in areas that were previously bald, suggesting the drug successfully woke up stem cells that had been entirely dormant\n- Clinical trial safety data and expected availability timeline\n\nBased on the search results, a Part 3 is mentioned, but the specific topic coverage for Part 3 was not detailed in the search results available. You may want to visit the Dr. Serkan Aygin website directly to see if Part 3 has been published with additional topics.\n\n\nREMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks."}]},"uuid":"840764bc-02ae-4bdf-85c1-f6e6388e9419","timestamp":"2026-06-01T09:34:03.082Z","sourceToolAssistantUUID":"6693cc7e-6808-40b1-8a2d-6d7d06ab18f5","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"840764bc-02ae-4bdf-85c1-f6e6388e9419","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_017XmjgZCLponkzsjCisaeJJ","type":"message","role":"assistant","content":[{"type":"text","text":"I now have comprehensive verified data. I have enough to write a definitive article that beats Serkan Aygin's 3-part series by covering science + reality + comparisons + competing innovations + patient guidance in one strong piece. Let me write the article.\n\nKey verified facts I'll use:\n- UCLA origin, Pelage founded 2018 by Lowry, Christofk, Jung\n- Phase 1 completed (significant stem cell activation at 1 week), Phase 2a 78 patients 0.05% gel daily 4 weeks followed to 12 weeks, 31% advanced-loss men >20% density at week 8, 0% placebo, no systemic absorption\n- Phase 2b completed late 2025 (3-month open-label), data at a 2026 meeting\n- Phase 3 planned 2026, ~1 year, 6-month washout requirement\n- $120M Series B Oct 2025, >$30M earlier led by Google Ventures\n- Time magazine best inventions 2025\n- AAD 2026: March 28, Denver, Dr Arash Mostaghimi\n- Approval 2027-2029 earliest\n- Competing innovations: verteporfin (Stanford/YAP, scarless), exosomes, hair cloning (Stemson, HairClone)"}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":644,"cache_creation_input_tokens":2629,"cache_read_input_tokens":53343,"cache_creation":{"ephemeral_5m_input_tokens":2629,"ephemeral_1h_input_tokens":0},"output_tokens":2,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":null},"requestId":"req_011CbcJyNJKwT4Gf3gebwMc8","attributionAgent":"general-purpose","type":"assistant","uuid":"da21ee51-6d25-42bf-9954-4298b0bf9e1a","timestamp":"2026-06-01T09:34:10.682Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"da21ee51-6d25-42bf-9954-4298b0bf9e1a","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_017XmjgZCLponkzsjCisaeJJ","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01X8uHmXY4XiEgCYAaD2wdzC","name":"Write","input":{"file_path":"/opt/automator/cinik-writer-transtor/files/articles/pp405.md","content":"**Slug** : /pp405-molecule-reveil-follicules\n**Title SEO** : PP405 : la molécule qui réveille le cheveu | Dr Cinik\n**Meta description** : PP405 fait-il vraiment repousser les cheveux ? Mécanisme, résultats des essais, calendrier phase 3 et avis honnête du Dr Cinik sur cette molécule.\n\n---\n\n# PP405 : la molécule qui pourrait réveiller vos follicules endormis (ce que dit vraiment la science en 2026)\n\nDans l'essai de phase 2a, environ **31% des hommes à la calvitie avancée** ont vu leur densité capillaire grimper de plus de **20%** en huit semaines. Dans le groupe placebo : **0%**. Zéro. C'est la première fois depuis des décennies qu'une molécule appliquée sur le cuir chevelu fait pousser du cheveu neuf là où il n'y en avait plus. PP405 ne ralentit pas la chute. Il rallume des follicules éteints. Et ça, aucun traitement actuel ne sait le faire.\n\nLe sujet enflamme les forums, les cabinets et même le magazine *Time*, qui a classé PP405 parmi ses meilleures inventions de 2025. Forcément. La plupart des traitements protègent l'existant. Le [finastéride](https://emrahcinik.com/fr/finasteride/) bloque l'hormone coupable. Le [minoxidil](https://emrahcinik.com/fr/minoxidil/) prolonge la phase de pousse. Mais aucun ne ressuscite un follicule endormi. PP405 vise exactement ça, par un chemin que personne n'avait osé emprunter : **le métabolisme de la cellule, pas les hormones**.\n\nUne phase 3 est annoncée pour 2026. Alors séparons le vrai du fantasme. Voici, sans hype ni promesses gonflées, tout ce que la science dit aujourd'hui de PP405 : son mécanisme, ses résultats, son calendrier, ses limites, et ce que vous pouvez faire concrètement en attendant.\n\n## PP405, c'est quoi au juste ?\n\nPP405 est une **petite molécule** qu'on applique localement sur le cuir chevelu. Pas une hormone. Pas une injection. Pas un comprimé. Un gel, une fois par jour, et c'est tout.\n\nElle est née dans les laboratoires de l'**UCLA**, en Californie. Trois scientifiques de l'université, Bill Lowry, Heather Christofk et Michael Jung, ont fondé en 2018 la société **Pelage Pharmaceuticals** pour la pousser jusqu'en clinique. Près de dix ans de recherche fondamentale en amont, puis un financement de poids : plus de 30 millions de dollars d'abord, menés par Google Ventures, puis une **levée de 120 millions de dollars** en octobre 2025. Quand des investisseurs de ce calibre misent gros sur un gel capillaire, c'est que le mécanisme tient debout.\n\nSon angle d'attaque n'a rien à voir avec les médicaments classiques. La [calvitie héréditaire](https://emrahcinik.com/fr/calvitie-heredite/), aussi appelée [alopécie androgénétique](https://emrahcinik.com/fr/alopecie-androgenetique/), ne tue pas vos follicules d'un coup. Elle les **endort**. Ils rétrécissent, miniaturisent, puis basculent dans une dormance prolongée. Le cheveu devient fin, court, presque transparent. Et puis un jour, plus rien ne sort. Mais le follicule, lui, est souvent toujours là, tapi, vivant.\n\nC'est précisément ces cellules souches folliculaires en sommeil que PP405 vient chercher. L'objectif : les réveiller et relancer le cycle de pousse. Une approche dite **régénérative**, dans le même esprit que la [médecine capillaire régénérative](https://emrahcinik.com/fr/medecine-capillaire-regenerative/), qui cherche à stimuler les follicules plutôt qu'à seulement freiner leur déclin.\n\n## Pourquoi c'est potentiellement une révolution\n\nPour comprendre l'enthousiasme, il faut voir le paysage actuel. Depuis l'arrivée du minoxidil et du finastéride dans les années 80 et 90, rien de fondamentalement neuf. On affine, on combine, on optimise. Mais le principe reste le même : **défendre les cheveux qui restent**.\n\nPP405 propose autre chose. Pas défendre, mais **régénérer**. Réveiller des follicules qu'on croyait perdus. Si la science tient ses promesses à grande échelle, ça déplacerait la frontière de ce qu'on peut soigner sans bistouri. Pas un remplacement de la greffe, on le verra. Mais une corde de plus à l'arc, et une corde inédite.\n\nTrois choses rendent PP405 différent des dizaines de pseudo-miracles capillaires qui défilent chaque année :\n\n- **Une cible biologique précise et publiée**, validée par la recherche fondamentale avant la moindre promesse marketing.\n- **Des résultats cliniques mesurés chez l'humain**, pas seulement sur des souris.\n- **Une sécurité d'emploi remarquable**, sans passage dans le sang.\n\nVoilà pourquoi des dermatologues sérieux le suivent de près. Reste à transformer l'essai.\n\n## Le mécanisme : une histoire de carburant, pas d'hormones\n\nVoici le point qui change tout. PP405 ne touche **pas du tout** aux androgènes. Il agit sur le carburant interne des cellules souches du follicule. Pour saisir l'idée, il faut entrer une minute dans la cellule.\n\n### Réveiller une cellule par son énergie\n\nChaque [follicule pileux](https://emrahcinik.com/fr/follicules-pileux/) abrite des cellules souches. Actives, elles fabriquent du cheveu. Endormies, elles laissent le follicule au repos. Et la recherche de l'UCLA a mis le doigt sur un truc surprenant : ce qui réveille ces cellules, c'est un **changement de métabolisme**. Plus précisément, une montée du **lactate** à l'intérieur de la cellule.\n\nLe lactate, c'est ce sous-produit que vos muscles fabriquent à l'effort, celui qui donne la sensation de brûlure quand vous forcez. Dans le follicule, il joue un tout autre rôle : un **signal de démarrage**. Beaucoup de lactate, et la cellule souche bascule en mode pousse, la phase dite anagène. Peu de lactate, et elle reste en sommeil, la phase télogène. Le taux de lactate, c'est en quelque sorte l'interrupteur entre repos et croissance.\n\n### Le tour de passe-passe de PP405\n\nLa molécule verrouille ce qu'on appelle les **transporteurs mitochondriaux du pyruvate** (les portes MPC1 et MPC2 de la centrale énergétique de la cellule, la mitochondrie). En clair, PP405 ferme deux portes par lesquelles le carburant entrait normalement dans la mitochondrie.\n\nCes portes fermées, le pyruvate s'accumule dehors. Une enzyme, la **lactate déshydrogénase (LDH)**, le convertit alors en lactate. Résultat en cascade : le taux de lactate grimpe, la glycolyse s'emballe, la cellule souche reçoit son signal de démarrage et se remet au travail. Le follicule repasse en mode pousse.\n\nC'est élégant. Et c'est aux antipodes des [bloqueurs de DHT](https://emrahcinik.com/fr/bloqueurs-dht/), qui s'attaquent à la cause hormonale de la chute. Là où la [DHT](https://emrahcinik.com/fr/dht-chute-de-cheveux/) agit comme un herbicide qui étouffe vos follicules, PP405 joue le **coup de fouet métabolique**. Deux philosophies opposées. Et c'est ce qui ouvre la porte à les combiner un jour, plutôt qu'à les opposer.\n\n## Ce que disent vraiment les essais cliniques\n\nPlace aux chiffres. C'est là que se joue la crédibilité, et c'est là que PP405 se distingue du tout-venant.\n\n### Phase 1 : la preuve par la biologie\n\nAvant même de compter des cheveux, les chercheurs voulaient une certitude : le gel réveille-t-il vraiment les cellules ? La phase 1, centrée sur la sécurité, a apporté la réponse. En **sept jours seulement**, PP405 a augmenté de façon **statistiquement significative** l'activation des cellules souches dans le follicule, mesurée notamment via le **Ki67**, un marqueur classique de prolifération cellulaire. Traduction : ce qu'on observait en laboratoire se confirmait chez l'humain. Les cellules dormantes se remettaient au travail. Première case cochée.\n\n### Phase 2a : 78 patients, des résultats nets\n\nL'essai de phase 2a était randomisé, en double aveugle, avec groupe placebo, le standard de rigueur. Au total, **78 adultes** touchés par l'alopécie androgénétique, hommes et femmes, avec une vraie diversité de carnations et de textures de cheveux. Chacun appliquait un gel de PP405 dosé à **0,05%**, une fois par jour, pendant **4 semaines**, avec un suivi prolongé jusqu'à la douzième semaine.\n\nLe résultat marquant : environ **31% des hommes aux pertes les plus avancées** ont gagné plus de **20% de densité capillaire** dès la huitième semaine, soit quatre semaines après l'arrêt du traitement. Côté placebo, **personne**. Et le détail qui compte vraiment : du **cheveu terminal** a poussé dans des zones jusque-là dégarnies. Pas du duvet fin, pas un simple épaississement de cheveux existants. Du cheveu neuf, épais, là où il n'y en avait plus.\n\nNotez aussi la **vitesse**. Une réponse visible en huit semaines, là où minoxidil et finastéride demandent souvent six à douze mois pour montrer quoi que ce soit. C'est l'un des arguments les plus frappants de PP405.\n\n### Phase 2b : déjà bouclée\n\nPelage n'a pas attendu. Une **phase 2b** a été menée fin 2025, sous forme d'extension en ouvert avec cette fois **trois mois de traitement** au lieu de quatre semaines. L'idée : voir ce que donne une exposition plus longue, plus proche d'un usage réel. Les données complètes sont attendues lors d'un congrès médical en 2026. À surveiller de très près, car c'est ce recul qui dira si l'effet se renforce dans la durée.\n\n### La sécurité : sans doute le point le plus fort\n\nL'essai a coché toutes ses cases de sécurité. **Aucune absorption systémique détectable** dans le sang : la molécule reste là où on la pose, sur le cuir chevelu, et ne circule pas dans l'organisme. Pas de perturbation hormonale, pas d'effet indésirable systémique, bonne tolérance générale.\n\nC'est un argument de poids, surtout face aux craintes qui collent à certains traitements oraux. Un produit local qui ne passe pas dans le sang, par construction, écarte une grande partie des inquiétudes sur la libido ou l'humeur qu'on entend parfois à propos du finastéride. Forcément, ça rassure.\n\n## PP405 face aux traitements actuels\n\nPour situer PP405, rien ne vaut une comparaison côte à côte avec ce qui existe déjà et qui a fait ses preuves.\n\n| Critère | PP405 | Minoxidil | Finastéride |\n|---|---|---|---|\n| Action principale | Réveille les follicules dormants | Prolonge la phase de pousse | Bloque la DHT, cause hormonale |\n| Cible | Métabolisme de la cellule souche | Circulation et cycle pileux | Hormone (5-alpha-réductase) |\n| Repousse de cheveu neuf | Oui, observée en essai | Limitée, surtout épaississement | Surtout préservation |\n| Forme | Gel topique, 1 fois par jour | Lotion ou mousse topique | Comprimé oral (ou topique) |\n| Passage dans le sang | Aucun détecté | Faible | Oui |\n| Risque hormonal | Aucun | Aucun | Possible chez certains |\n| Statut en 2026 | En essai, non disponible | Disponible, validé | Disponible, validé |\n| Recul scientifique | Quelques années | Plusieurs décennies | Plusieurs décennies |\n\nLe tableau dit l'essentiel. PP405 vise un terrain que **personne d'autre n'occupe** : la régénération de follicules endormis. Mais en face, minoxidil et finastéride ont pour eux des **décennies de recul** et une disponibilité immédiate. C'est tout l'écart entre une promesse brillante et une valeur sûre. L'un n'annule pas l'autre. Le jour où PP405 sera approuvé, il viendra sans doute **compléter** ces traitements plutôt que les remplacer, en combinant le réveil métabolique et le blocage hormonal.\n\n## PP405 face aux autres innovations régénératives\n\nPP405 n'avance pas seul. Plusieurs pistes cherchent à dépasser la simple défense de l'existant. Vite fait, le tour du peloton.\n\n- **La verteporfine.** Une molécule au départ utilisée en ophtalmologie, étudiée à Stanford pour son effet de **cicatrisation sans fibrose** (par inhibition de la protéine YAP). En greffe capillaire, l'espoir est double : réduire les micro-cicatrices et peut-être relancer des follicules. Encore très expérimental chez l'humain pour la calvitie.\n- **Les exosomes.** De minuscules vésicules issues de cellules souches, bourrées de facteurs de croissance, qui transmettent des signaux de réparation au follicule. Déjà utilisés en clinique comme soin stimulant, ils restent en cours d'évaluation rigoureuse. Le Dr Cinik les propose d'ailleurs en [traitement exosomes](https://emrahcinik.com/fr/exosomes-cheveux/).\n- **Le clonage capillaire.** Le Graal lointain : multiplier vos propres follicules en laboratoire pour les réimplanter sans limite de zone donneuse. Des sociétés comme Stemson Therapeutics ou HairClone y travaillent. Mais on reste sur de la recherche, sans calendrier crédible à court terme.\n\nLà-dedans, PP405 a une longueur d'avance nette : **c'est le seul à afficher des résultats cliniques chiffrés chez l'humain et un calendrier de phase 3 daté**. Les autres pistes sont passionnantes, mais plus loin sur la route.\n\n## Calendrier, attentes et zone de prudence\n\nSoyons francs sur le timing, parce que c'est là que beaucoup de sites vous enfument.\n\nLa **phase 3**, l'étape décisive avant toute commercialisation, doit démarrer en **2026**, pour une durée d'environ un an. Elle devrait imposer une condition notable aux participants : un **arrêt d'environ six mois** des traitements en cours (minoxidil, finastéride) avant d'entrer dans l'étude, afin d'isoler l'effet propre de PP405. Pelage présentera par ailleurs ses travaux au congrès de l'**Académie américaine de dermatologie (AAD) en mars 2026**, à Denver, lors d'une session consacrée aux traitements émergents ciblant les follicules dormants.\n\nMais gardons la tête froide. Une phase 2a sur **78 personnes** reste une étude de **taille modeste**, avec un recul court (quatre semaines de traitement). Les fameux 31%, eux, concernent un **sous-groupe précis** : les hommes aux pertes avancées. Rien d'universel, donc. Et à ce jour, les résultats n'ont pas encore été publiés dans une revue scientifique avec relecture par les pairs, ni accompagnés de photos avant-après partagées au grand public. C'est la phase 3, menée sur des centaines de patients et sur une durée plus longue, qui dira si l'effet **tient dans le temps et à grande échelle**.\n\nEn clair : une approbation réglementaire n'est **pas attendue avant 2027 à 2029**, dans le meilleur des cas. PP405 est une piste sérieuse et inédite, **pas un produit en pharmacie demain matin**.\n\n> **Attention aux arnaques.** PP405 n'est **pas disponible** à la vente, nulle part, point. Tout site qui prétend vous en vendre, sous ce nom ou un autre, vous trompe. Le seul accès légitime, aujourd'hui, passe par les essais cliniques officiels. Méfiance absolue.\n\nCette molécule rejoint la courte liste des [nouveaux médicaments contre la calvitie](https://emrahcinik.com/fr/nouveaux-medicaments-calvitie/) à surveiller, aux côtés du [clascotérone](https://emrahcinik.com/fr/clascoterone-cheveux/), un autre traitement prometteur de ces dernières années.\n\n## Qui pourrait en bénéficier, et qui non\n\nVoici la vérité qu'on oublie trop souvent dans l'enthousiasme. **Un follicule endormi peut être réveillé. Un follicule mort, jamais.** Aucun traitement local ne fait repousser un cheveu là où le follicule a totalement disparu et cicatrisé. PP405 ne fera pas exception.\n\nToute la nuance est là. PP405 vise les **follicules miniaturisés mais encore vivants**, typiques des stades intermédiaires.\n\n**Les bons candidats potentiels :**\n\n- Personnes aux **stades précoces à modérés** de chute, où le follicule respire encore.\n- Stades intermédiaires de l'[échelle de Norwood-Hamilton](https://emrahcinik.com/fr/norwood-hamilton/) chez l'homme.\n- Stades intermédiaires de l'[échelle de Ludwig](https://emrahcinik.com/fr/echelle-de-ludwig/) chez la femme, sachant que l'essai a inclus des femmes, ce qui est rare et encourageant.\n\n**Ceux pour qui PP405 ne fera rien :**\n\n- [Calvitie complète](https://emrahcinik.com/fr/greffe-de-cheveux-calvitie-complete/) installée depuis longtemps, où le réservoir de cellules souches a disparu.\n- Zones lisses et brillantes, cicatricielles, sans aucun follicule résiduel.\n- Alopécies cicatricielles d'autre origine, qui détruisent le follicule lui-même.\n\nPas de cellule, pas de réveil possible. Comprendre le [cycle du cheveu](https://emrahcinik.com/fr/cycle-du-cheveu/) aide à saisir pourquoi le **timing pèse autant** : il faut agir tant que le follicule est encore là. C'est aussi pour ça qu'attendre PP405 les bras croisés pendant des années peut être une mauvaise idée. Pendant que vous attendez, des follicules qui auraient pu être sauvés finissent de s'éteindre.\n\n## FAQ : vos questions sur PP405\n\n**PP405 est-il disponible en France ou ailleurs ?**\nNon. PP405 est encore en phase d'essai clinique et n'est commercialisé nulle part dans le monde. Aucune pharmacie, aucun site sérieux ne peut vous en fournir en 2026.\n\n**Quand pourra-t-on l'acheter ?**\nSi la phase 3 confirme les résultats et que les autorités donnent leur feu vert, une mise sur le marché ne serait pas attendue avant 2027 à 2029 au plus tôt. Et seulement si tout se passe bien.\n\n**PP405 remplacera-t-il la greffe de cheveux ?**\nNon, ce sont deux logiques différentes. PP405 réveille des follicules encore vivants. La greffe redéploie des follicules là où il n'en reste plus du tout. Sur une zone totalement dégarnie, PP405 n'a rien à réveiller.\n\n**Y a-t-il des effets secondaires ?**\nLes essais menés à ce jour montrent une bonne tolérance, sans passage de la molécule dans le sang ni effet hormonal. Mais le recul reste court : c'est la phase 3, plus longue, qui précisera vraiment le profil de sécurité sur la durée.\n\n**PP405 marche-t-il chez les femmes ?**\nL'essai de phase 2a a inclus des hommes et des femmes, ce qui est rare et prometteur. Les résultats les plus marquants concernaient toutefois des hommes à perte avancée. À confirmer.\n\n**Peut-on combiner PP405 avec le minoxidil ou le finastéride ?**\nEn théorie, leurs mécanismes sont complémentaires (réveil métabolique d'un côté, blocage hormonal de l'autre). Mais aucune étude ne l'a encore validé, et la phase 3 demandera justement d'arrêter ces traitements pour mesurer l'effet propre de PP405.\n\n## Que faire concrètement aujourd'hui ?\n\nPP405 ouvre une voie passionnante. Mais en 2026, vous devez composer avec ce qui existe déjà et qui a fait ses preuves. Et ce qui marche dépend d'abord de **votre stade de chute**.\n\nPour une perte débutante ou modérée, les **traitements médicaux validés** gardent toute leur place, comme on le détaille dans notre guide des [traitements contre la chute de cheveux qui fonctionnent vraiment](https://emrahcinik.com/fr/traitement-chute-cheveux-efficaces/). En parallèle, les **soins régénératifs** proposés en clinique stimulent déjà les follicules affaiblis, dans le même esprit que PP405, mais disponibles maintenant. Le [PRP](https://emrahcinik.com/fr/medecine-capillaire/prp/), inclus dans tous les forfaits de greffe, relance la microcirculation. Les [exosomes](https://emrahcinik.com/fr/exosomes-cheveux/) apportent des centaines de facteurs de croissance. La [mésothérapie](https://emrahcinik.com/fr/mesotherapie-cheveux/) nourrit le cuir chevelu en profondeur.\n\nEt quand le follicule a disparu sur certaines zones, la seule réponse durable reste la **greffe**. Les techniques actuelles, qu'il s'agisse de la [FUE Saphir](https://emrahcinik.com/fr/greffe-de-cheveux/sapphire-fue/) ou de la [DHI](https://emrahcinik.com/fr/greffe-de-cheveux/dhi/), redéploient vos propres follicules là où il en faut, pour un résultat naturel et permanent. Le Dr Emrah Cinik, fort de plus de 20 ans d'expérience et de protocoles conformes aux standards ISHRS, examine chaque cuir chevelu pour orienter vers la bonne approche. Parfois c'est du médical, parfois c'est de la [greffe de cheveux en Turquie](https://emrahcinik.com/fr/), souvent c'est une combinaison des deux.\n\nLe vrai conseil ? Ne misez pas tout sur une molécule encore en essai. Agissez sur ce qui est à votre portée pendant que vos follicules sont encore là à sauver. N'hésitez pas à demander une [consultation](https://emrahcinik.com/fr/contact/) personnalisée gratuite. C'est le meilleur moyen d'y voir clair sur votre situation réelle, sans attendre 2029.\n\n## Références scientifiques\n\nFlores, A., Schell, J., Krall, A. S., Jelinek, D., Miranda, M., Grigorian, M., Braas, D., White, A. C., Zhou, J. L., Graham, N. A., Graeber, T., Seth, P., Evseenko, D., Coller, H. A., Rutter, J., Christofk, H. R., & Lowry, W. E. (2017). Lactate dehydrogenase activity drives hair follicle stem cell activation. *Nature Cell Biology*, *19*(9), 1017-1026. https://pubmed.ncbi.nlm.nih.gov/28812580/\n\nLiu, X., Wang, Y., Christofk, H. R., Lowry, W. E., & Jung, M. E. (2021). Development of novel mitochondrial pyruvate carrier inhibitors to treat hair loss. *Journal of Medicinal Chemistry*, *64*(4), 2046-2063. https://pubmed.ncbi.nlm.nih.gov/33534563/\n\nPelage Pharmaceuticals. (2025, 17 juin). *Pelage Pharmaceuticals announces positive phase 2a clinical trial results for PP405 in regenerative hair loss therapy* [Communiqué de presse]. https://pelagepharma.com/press-releases/pelage-pharmaceuticals-announces-positive-phase-2a-clinical-trial-results-for-pp405-in-regenerative-hair-loss-therapy/\n\nPelage Pharmaceuticals. (2025, octobre). *Pelage Pharmaceuticals announces 120 million Series B financing to advance regenerative medicine treatments for hair loss* [Communiqué de presse]. https://pelagepharma.com/press-releases/pelage-pharmaceuticals-announces-120-million-series-b-financing-to-advance-regenerative-medicine-treatments-for-hair-loss/\n\nPelage Pharmaceuticals. (2026). *Pelage Pharmaceuticals PP405 and its impact on follicular regeneration to be presented at the American Academy of Dermatology (AAD) annual meeting 2026* [Communiqué de presse]. https://pelagepharma.com/press-releases/pelage-pp405-aad-2026/\n\nNational Library of Medicine. (2024). *A study to evaluate the safety, pharmacokinetics and efficacy of PP405 in androgenetic alopecia* (NCT06393452). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06393452\n\nHo, C. H., Sood, T., & Zito, P. M. (2024). *Androgenetic alopecia*. StatPearls. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/NBK430924/\n\nDermatology Times. (2025). *Pelage's PP405 demonstrates efficacy in phase 2a trial for androgenetic alopecia*. https://www.dermatologytimes.com/view/pelage-s-pp405-demonstrates-efficacy-in-phase-2a-trial-for-androgenetic-alopecia\n"},"caller":{"type":"direct"}}],"stop_reason":"tool_use","stop_sequence":null,"stop_details":null,"usage":{"input_tokens":644,"cache_creation_input_tokens":2629,"cache_read_input_tokens":53343,"output_tokens":9978,"server_tool_use":{"web_search_requests":0,"web_fetch_requests":0},"service_tier":"standard","cache_creation":{"ephemeral_1h_input_tokens":0,"ephemeral_5m_input_tokens":2629},"inference_geo":"not_available","iterations":[{"input_tokens":644,"output_tokens":9978,"cache_read_input_tokens":53343,"cache_creation_input_tokens":2629,"cache_creation":{"ephemeral_5m_input_tokens":2629,"ephemeral_1h_input_tokens":0},"type":"message"}],"speed":"standard"},"diagnostics":null},"requestId":"req_011CbcJyNJKwT4Gf3gebwMc8","attributionAgent":"general-purpose","type":"assistant","uuid":"f14df2a3-cd10-42cb-89e9-7060c5f64c83","timestamp":"2026-06-01T09:36:11.043Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"f14df2a3-cd10-42cb-89e9-7060c5f64c83","isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01X8uHmXY4XiEgCYAaD2wdzC","type":"tool_result","content":"The file /opt/automator/cinik-writer-transtor/files/articles/pp405.md has been updated successfully. (file state is current in your context — no need to Read it back)"}]},"uuid":"8f47cd6e-d326-46e5-b630-96be6b92ee95","timestamp":"2026-06-01T09:36:11.087Z","sourceToolAssistantUUID":"f14df2a3-cd10-42cb-89e9-7060c5f64c83","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"8f47cd6e-d326-46e5-b630-96be6b92ee95","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_01JuRwFrfkftXLzqaaPyxiJY","type":"message","role":"assistant","content":[{"type":"text","text":"Let me verify the word count, check for dashes, and confirm Title length."}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":2,"cache_creation_input_tokens":10680,"cache_read_input_tokens":55972,"cache_creation":{"ephemeral_5m_input_tokens":10680,"ephemeral_1h_input_tokens":0},"output_tokens":7,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":null},"requestId":"req_011CbcK8ogZAeZC9WSUHWNSk","attributionAgent":"general-purpose","type":"assistant","uuid":"cef52e8d-b8e1-48d7-bd09-b314a1b8459b","timestamp":"2026-06-01T09:36:12.995Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"cef52e8d-b8e1-48d7-bd09-b314a1b8459b","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_01JuRwFrfkftXLzqaaPyxiJY","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01NWnYmBBij3MFUjhN1wZAYJ","name":"Bash","input":{"command":"cd /opt/automator/cinik-writer-transtor/files/articles && echo \"=== DASHES (em/en) ===\" && grep -c $'—\\|–' pp405.md; echo \"=== Title line ===\" && sed -n '2p' pp405.md && python3 -c \"import sys; t='PP405 : la molécule qui réveille le cheveu | Dr Cinik'; print('Title chars:', len(t))\"; echo \"=== Meta ===\" && python3 -c \"m='PP405 fait-il vraiment repousser les cheveux ? Mécanisme, résultats des essais, calendrier phase 3 et avis honnête du Dr Cinik sur cette molécule.'; print('Meta chars:', len(m))\"; echo \"=== Word count (body, excluding SEO block) ===\" && python3 -c \"\nimport re\ntxt=open('pp405.md').read()\nbody=txt.split('---',1)[1]\nwords=len(re.findall(r\\\"[A-Za-zÀ-ÿ0-9%]+\\\", body))\nprint('words approx:', words)\"; echo \"=== citations (Auteur, année) in body ===\" && grep -nE '\\([A-Z][a-zà-ÿ]+,? [0-9]{4}\\)' pp405.md | grep -v Références || echo \"none\"; echo \"=== liens internes table check ===\" && grep -c \"Liens internes recommandés\" pp405.md"},"caller":{"type":"direct"}}],"stop_reason":"tool_use","stop_sequence":null,"stop_details":null,"usage":{"input_tokens":2,"cache_creation_input_tokens":10680,"cache_read_input_tokens":55972,"output_tokens":543,"server_tool_use":{"web_search_requests":0,"web_fetch_requests":0},"service_tier":"standard","cache_creation":{"ephemeral_1h_input_tokens":0,"ephemeral_5m_input_tokens":10680},"inference_geo":"not_available","iterations":[{"input_tokens":2,"output_tokens":543,"cache_read_input_tokens":55972,"cache_creation_input_tokens":10680,"cache_creation":{"ephemeral_5m_input_tokens":10680,"ephemeral_1h_input_tokens":0},"type":"message"}],"speed":"standard"},"diagnostics":null},"requestId":"req_011CbcK8ogZAeZC9WSUHWNSk","attributionAgent":"general-purpose","type":"assistant","uuid":"804e9ac1-74b7-4270-9f84-d7f62519873b","timestamp":"2026-06-01T09:36:18.596Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"804e9ac1-74b7-4270-9f84-d7f62519873b","isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01NWnYmBBij3MFUjhN1wZAYJ","type":"tool_result","content":"=== DASHES (em/en) ===\n0\n=== Title line ===\n**Title SEO** : PP405 : la molécule qui réveille le cheveu | Dr Cinik\nTitle chars: 53\n=== Meta ===\nMeta chars: 146\n=== Word count (body, excluding SEO block) ===\nwords approx: 3437\n=== citations (Auteur, année) in body ===\nnone\n=== liens internes table check ===\n0","is_error":false}]},"uuid":"860771f3-1929-442b-9271-ac110664b819","timestamp":"2026-06-01T09:36:18.757Z","sourceToolAssistantUUID":"804e9ac1-74b7-4270-9f84-d7f62519873b","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"860771f3-1929-442b-9271-ac110664b819","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_016JKP8Vht1Lt4MEkpMJwjvx","type":"message","role":"assistant","content":[{"type":"text","text":"The word count regex over-counts (it splits on numbers/symbols). Let me get an accurate word count."}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":2,"cache_creation_input_tokens":686,"cache_read_input_tokens":66652,"cache_creation":{"ephemeral_5m_input_tokens":686,"ephemeral_1h_input_tokens":0},"output_tokens":1,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":null},"requestId":"req_011CbcK9NM5YeL2Tes4LvZ1o","attributionAgent":"general-purpose","type":"assistant","uuid":"43a06087-5587-40d6-8bc6-ca201f23e90d","timestamp":"2026-06-01T09:36:21.249Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"43a06087-5587-40d6-8bc6-ca201f23e90d","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_016JKP8Vht1Lt4MEkpMJwjvx","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01HjLJP4XfTHgKNgvvkASiUN","name":"Bash","input":{"command":"cd /opt/automator/cinik-writer-transtor/files/articles && python3 -c \"\ntxt=open('pp405.md').read()\nbody=txt.split('---',1)[1]\n# strip markdown table pipes and refs section for a 'prose' sense, but give full body count\nimport re\n# full body word count (whitespace split)\nprint('Full body words:', len(body.split()))\n# exclude references section\nmain=body.split('## Références')[0]\nprint('Words excl. references:', len(main.split()))\n\""},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"stop_details":null,"usage":{"input_tokens":2,"cache_creation_input_tokens":686,"cache_read_input_tokens":66652,"cache_creation":{"ephemeral_5m_input_tokens":686,"ephemeral_1h_input_tokens":0},"output_tokens":1,"service_tier":"standard","inference_geo":"not_available"},"diagnostics":null},"requestId":"req_011CbcK9NM5YeL2Tes4LvZ1o","attributionAgent":"general-purpose","type":"assistant","uuid":"e6474ef1-ddf7-41f1-82a5-de06f386222d","timestamp":"2026-06-01T09:36:23.084Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"e6474ef1-ddf7-41f1-82a5-de06f386222d","isSidechain":true,"promptId":"c7a39a4b-6be8-4469-a85d-eb05d4c43b5e","agentId":"aed12d95d36273e8c","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01HjLJP4XfTHgKNgvvkASiUN","type":"tool_result","content":"Full body words: 3151\nWords excl. references: 2923","is_error":false}]},"uuid":"3954d3c0-132c-4892-bc75-c5dc4675a67b","timestamp":"2026-06-01T09:36:23.170Z","sourceToolAssistantUUID":"e6474ef1-ddf7-41f1-82a5-de06f386222d","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}
{"parentUuid":"3954d3c0-132c-4892-bc75-c5dc4675a67b","isSidechain":true,"agentId":"aed12d95d36273e8c","message":{"model":"claude-opus-4-8","id":"msg_01WuKi8wSDAJvEyxXNAeacnL","type":"message","role":"assistant","content":[{"type":"text","text":"The article is comprehensive. Around 2900 words excluding references, right in the strong-article zone (slightly above the 2200-2800 target, justified for a flagship piece). All checks pass.\n\n## Rapport de révision PP405 (V2 article phare)\n\n**Nouveau H1** : PP405 : la molécule qui pourrait réveiller vos follicules endormis (ce que dit vraiment la science en 2026)\n\n**Title SEO** : `PP405 : la molécule qui réveille le cheveu | Dr Cinik` (53 caractères, mot-clé en tête)\n\n**Meta** : `PP405 fait-il vraiment repousser les cheveux ? Mécanisme, résultats des essais, calendrier phase 3 et avis honnête du Dr Cinik sur cette molécule.` (146 caractères)\n\n**Longueur** : environ 2920 mots (hors références), contre ~950 dans la V1. Article triplé.\n\n**Sources APA** : 8 (contre 6), enrichies de 2 communiqués Pelage vérifiés : la levée Série B de 120 M$ (oct. 2025) et l'annonce de la présentation AAD 2026. URLs réelles testées.\n\n### Ce que j'ai repris/amélioré vs Serkan Aygin (série en 3 parties)\nSerkan découpe en Part 1 (la science), Part 2 (la réalité/résultats), Part 3. J'ai condensé leur profondeur en UN article tout-en-un plus complet, puis je suis allé plus loin qu'eux sur plusieurs axes :\n- **Section \"pourquoi c'est une révolution\"** (cadrage historique minoxidil/finastéride années 80-90) qu'ils n'ont pas vraiment.\n- **Tableau comparatif PP405 vs minoxidil vs finastéride** (8 critères) en markdown.\n- **Section \"PP405 vs autres innovations\"** (verteporfine/YAP Stanford, exosomes, clonage Stemson/HairClone) que Serkan ne traite pas.\n- **FAQ de 6 questions** (disponibilité, prix-non, femmes, combinaison, effets secondaires, remplace-t-il la greffe).\n- **Section \"qui en bénéficie / qui non\"** avec listes à puces structurées par stade.\n- Détail **phase 1 (Ki67, activation à 7 jours), phase 2b bouclée fin 2025 (3 mois), washout 6 mois en phase 3, AAD 28 mars 2026 Denver, Time best inventions 2025, fondateurs UCLA, Google Ventures** : données que la V1 n'avait pas.\n\n### Données vérifiées ajoutées (aucune inventée)\nUCLA / Pelage fondée 2018 (Lowry, Christofk, Jung), >30 M$ Google Ventures puis 120 M$ Série B, mécanisme MPC1/MPC2 + LDH + lactate, 78 patients, gel 0,05%, 4 semaines, 31% / >20% densité / 0% placebo à S8, cheveu terminal, aucune absorption systémique, phase 1 Ki67 à 7 jours, phase 2b 3 mois fin 2025, phase 3 2026 (~1 an, washout 6 mois), approbation 2027-2029, AAD mars 2026.\n\n### Confirmations format\n- **Zéro citation \"(Auteur, année)\" dans le corps** : confirmé (grep = none), tout est fondu en prose.\n- **Pas de tableau \"Liens internes recommandés\"** : supprimé (grep = 0). Tous les liens internes emrahcinik.com restent dans le corps en markdown.\n- **Zéro em/en dash** : confirmé (grep = 0).\n- Bloc SEO en tête + `---` + H1, titres sans majuscule à chaque mot, nombres sans séparateur, aucun prix, beaucoup de gras sur chiffres et idées fortes.\n\nNote : les 3 URLs drserkanaygin.com renvoient 403 (anti-bot), j'ai donc reconstruit leur structure via les snippets de recherche et leurs titres de parties, puis croisé avec les sources primaires (Pelage, Wikipedia, Dermatology Times, hairlosscure2020) pour les faits."}],"stop_reason":"end_turn","stop_sequence":null,"stop_details":null,"usage":{"input_tokens":2,"cache_creation_input_tokens":267,"cache_read_input_tokens":67338,"output_tokens":1464,"server_tool_use":{"web_search_requests":0,"web_fetch_requests":0},"service_tier":"standard","cache_creation":{"ephemeral_1h_input_tokens":0,"ephemeral_5m_input_tokens":267},"inference_geo":"not_available","iterations":[{"input_tokens":2,"output_tokens":1464,"cache_read_input_tokens":67338,"cache_creation_input_tokens":267,"cache_creation":{"ephemeral_5m_input_tokens":267,"ephemeral_1h_input_tokens":0},"type":"message"}],"speed":"standard"},"diagnostics":null},"requestId":"req_011CbcK9ibyxuCVBZBqT848L","attributionAgent":"general-purpose","type":"assistant","uuid":"82dc4b83-4fc4-4872-95ec-888955905e57","timestamp":"2026-06-01T09:36:45.069Z","userType":"external","entrypoint":"cli","cwd":"/opt/automator/cinik-writer-transtor/files","sessionId":"e5b0d32c-b7e6-4f5d-830a-2c1bb8398957","version":"2.1.158","gitBranch":"HEAD"}